Clinical trial NCT02774005
Conditions: Leber's Hereditary Optic Neuropathy (LHON)
Sponsor: Santhera Pharmaceuticals
Start date: 2016-05-01; Completion date: 2021-03-29
Enrollment: 199 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.

Detailed description:

Arms: arm 1: None
Interventions: intervention 1: Idebenone
Intervention descriptions: intervention 1: None

Protocol documents:
Prot_000.pdf: 
 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 1 of 50 
 
 
CLINICAL TRIAL PROTOCOL 
 
 
 
External Natural History Controlled, Open-Label Intervention Study to 
Assess the Efficacy and Safety of Long-Term Treatment with 
Idebenone (Raxone®) in Leber’s Hereditary Optic Neuropathy (LHON)  
 
(LEROS) 
Open-Label Study to assess the Efficacy and Safety of Idebenone in 
LHON Patients 
 
Compound: 
idebenone 
Phase: 
III (US)/ IV (EU) 
Protocol Number: 
SNT-IV-005 
Version: 
2.1_US 
Date: 
Study Acronym: 
6 March 2019 
LEROS 
EudraCT Number: 
2015-004405-16 
US IND Number: 
107,390 
 
 
 
 
 
 
Property of Santhera Pharmaceuticals (Switzerland) Limited 
 
 
 
Confidentiality Statement 
This document contains confidential information belonging to Santhera Pharmaceuticals (Switzerland) 
Ltd. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to 
hold this information in confidence and not copy or disclose it to others (except where required by 
applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of 
this obligation, Santhera Pharmaceuticals (Switzerland) Ltd. must be promptly notified. 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 2 of 50 
 
Study Administrative Structure 
 
Name: 
Santhera Pharmaceuticals (Switzerland) Limited 
Responsibility: 
Address: 
Sponsor 
Hohenrainstrasse 24 
4133 Pratteln, Switzerland 
Phone: 
+41 61 906 89 50 
Fax: 
+41 61 906 89 51 
 
 
Name: 
Antonio Perez, MD 
Responsibility: 
Clinical Research Physician 
Address 
Phone: 
Santhera Pharmaceuticals (Switzerland) Ltd 
+41 79 602 8998 
Fax: 
+41 61 906 8951 
e-mail: 
toni.perez@santhera.com 
 
 
Name: 
Responsibility: 
Address: 
Phone: 
e-mail: 
Andrea Elischer 
Clinical Trial Leader 
Santhera Pharmaceuticals (Switzerland) Ltd 
+41 61 906 89 07 
andrea.elischer@santhera.com 
 
 
 
Name: 
Omer De Mol 
Responsibility: 
Head of Drug Safety and Pharmacovigilance 
Address: 
Phone: 
Santhera Pharmaceuticals (Switzerland) Ltd 
+41 61 906 8904 
Fax: 
+41 61 906 8951  
e-mail: 
Omer.deMol@santhera.com  
 
 
Name: 
IQVIA (previously called Quintiles IMS) 
Responsibility: 
Monitoring, data management, Statistics 
Address: 
500 Brook Drive 
Green Park 
Reading, Berkshire, RG2 6UU, United Kingdom 
 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 3 of 50 
 
Notification in case of Serious Adverse Events and Adverse Events of Special Interest 
(AESI): 
Name: 
United BioSource Corporation 
EU Safety Services 
Address: 
16, Chemin des Coquelicots 
CH-1214 Vernier/Geneva, Switzerland 
Phone: 
+41 22 596 44 44 
Fax: 
+41 22 596 44 46 
e-mail: 
EUSafety@ubc.com 
 
 
 
 
Investigators / Investigational Sites:  
This is a multinational study that includes U.S sites operating under the IND and foreign sites 
not under the IND. 
 
Principal investigator (IND site) 
Name: 
Dr. Marc. H. Levin, MD, PhD 
Address: 
Department of Ophthalmology 
 
Palo Alto Medical Foundation 
 
301 Industrial Road, Fourth Floor 
 
San Carlos, CA 94070 
Phone: 
+1-650-596-4220 
Fax: 
+1-650-508-8540 
e-mail:  
levinmh@pamf.org  
 
 
Principal investigator (Non-IND site) 
Name: 
Prof. Dr. med. Thomas Klopstock 
Address: 
Friedrich-Baur-Institut an der Neurologischen Klinik 
Klinikum der Universität München - Innenstadt  
Ziemssenstr. 1; 80336 München; Germany 
Phone: 
+49-89-4400-57474 
Fax: 
+49-89-4400-57402 
e-mail: 
tklopsto@med.lmu.de 
 
 
 
For further investigators / Investigational sites: See separate listing. 
 
 
 




 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 5 of 50 
 
Synopsis 
 
Study Title 
External Natural History Controlled, open-Label Intervention Study to 
Assess the Efficacy and Safety of Long-Term Treatment with idebenone in 
Leber’s Hereditary Optic Neuropathy (LHON) 
Study Number 
SNT-IV-005 
Study Phase 
III (US)/ IV (EU) 
Study Acronym 
LEROS 
Planned Study Duration 
Up to 49 months including 24 months for recruitment, 24 months of 
treatment and 1 month for follow up visit 
Investigational Product 
Dosage and Route of 
Administration 
Idebenone 150 mg tablets (Raxone® is the branded name in the EU) 
900 mg/day (2 x 150 mg to be taken orally 3 times daily with meals) 
Control Group 
 
Natural history visual acuity outcomes in idebenone naïve patients 
collected as case record survey will be used as an external control group 
Indication 
Leber’s Hereditary Optic Neuropathy (LHON) 
Study Objectives 
Primary Objective: 
 
To assess efficacy of idebenone in the promotion of recovery or 
stabilization of visual acuity (VA) in patients treated with idebenone ≤1 
year after the onset of symptoms, compared to an external natural 
history control group of idebenone naïve patients 
Secondary Objectives: 
 
To assess efficacy of idebenone in the promotion of recovery or 
stabilization of visual acuity in LHON patients treated with >1 year after 
the onset of symptoms, compared to an external natural history control 
group of idebenone naïve patients 
 
To compare the promotion of recovery or stabilization of visual acuity 
in LHON patients treated with idebenone ≤1 and >1 year after the onset 
of symptoms  
 
To assess the influence of mutation on the promotion of recovery or 
stabilization of visual acuity in LHON patients treated with idebenone  
 
To assess the influence of time since onset of symptoms prior to the 
initiation of treatment with idebenone on the promotion of recovery or 
stabilization of visual acuity in LHON patients 
 
To assess the influence of duration of treatment with idebenone on 
changes in visual acuity in LHON patients 
 
To assess safety of long-term treatment of LHON patients with 
idebenone  
Study Endpoints 
Primary Endpoint: 
 
Proportion of eyes with clinically relevant recovery of visual acuity from 
Baseline or in which Baseline VA better than 1.0 logMAR was 
maintained at Month 12 in patients treated with idebenone ≤1 year after 
the onset of symptoms, compared to matching external natural history 
control group  
Clinically Relevant Recovery (CRR) is defined as a change from “off-chart” 
visual acuity to at least 1.6 logMAR value or an improvement of at least 0.2 
logMAR value within “on-chart”. 
Secondary Endpoints:  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 6 of 50 
 
 
Components of the primary endpoint: 
- 
Proportion of eyes with CRR of VA from Baseline at Month 12 
compared to matching external natural history control group 
- 
Proportion of eyes in which Baseline VA better than 1.0 logMAR 
was maintained at Month 12 compared to matching external 
natural history control group 
 
Proportion of eyes in patients treated with idebenone >1 year after the 
onset of symptoms with CRR of VA from Baseline or in which Baseline 
VA better than 1.0 logMAR was maintained at Month 12 compared to 
the external natural history control group, in all patients and classified 
by mutation 
 
Proportion of eyes and patients treated with idebenone ≤1 year after 
the onset of symptoms with CRR of VA from Baseline or in which 
Baseline visual acuity better than 1.0 logMAR was maintained following 
6, 18 and 24 months of treatment with idebenone compared to 
matching external natural history control group, in all patients and 
classified by mutation 
 
Proportion of eyes/patients treated with idebenone ≤1 year or >1 year 
after the onset of symptoms with “Off-chart” VA at Baseline in whom 
VA improves to better than 1.60 logMAR by Month 6, 12, 18 and 24  
 
Proportion of eyes/patients treated with idebenone ≤1 year or >1 year 
after the onset of symptoms with VA in the categories of better than 1.0 
logMAR, 1.0 to 1.68 logMAR and above 1.68 logMAR at each 
assessment time point up to Month 24 
 
Safety as assessed by AE count and laboratory analyses during the 
study 
Background and 
Rationale 
The 
randomized, 
placebo-controlled 
RHODOS 
(SNT-II-003) 
trial 
(Klopstock et al., 2011), the retrospective cohort study of Carelli et al., 
(2011), Santhera’s ongoing Expanded Access Program (EAP) and several 
case reports (summarized in Gueven and Faldu, 2013), provide evidence 
that idebenone promotes the recovery of VA in patients with LHON. 
However, due to the nature of these datasets, this evidence is not 
considered comprehensive. In view of the urgent medical need and poor 
prognosis of LHON if untreated, a randomized, placebo-controlled study to 
provide comprehensive data is not considered feasible in LHON. An open-
label study is therefore considered the most appropriate strategy for 
gathering additional evidence for the efficacy of idebenone in the treatment 
of LHON. The primary objective of this study is therefore to compare the 
outcomes for patients treated with Idebenone in this study with those of 
matching untreated patients from an external natural history control group 
generated in a historical case record survey (CRS). 
 
In RHODOS, LHON patients enrolling up to 5 years after the onset of 
symptoms of disease were treated with idebenone. Whilst natural history 
VA outcomes data collected from LHON patients early in the course of the 
disease is available, relatively little reliable natural history VA outcomes 
data is available from patients with longer disease durations. The primary 
endpoint of this study will therefore compare the VA outcomes for patients 
treated with idebenone ≤1 year of the onset of symptoms with matching 
natural history control data. Secondary endpoints will include outcomes for 
patients treated with idebenone >1 year after the onset of symptoms. Since 
LHON is known to lead to the apoptotic loss of retinal ganglion cells where 
the extent of loss increases with time since onset of disease, this study will 
explore further the relationship between time since onset at the initiation of 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 7 of 50 
 
idebenone therapy and CRR, where possible compared to untreated 
control patients. 
 
The treatment duration in RHODOS was 6 months and a larger proportion 
of idebenone-treated patients presented with CRR in VA compared to 
placebo. However, data from Santhera’s ongoing Expanded Access 
Program (EAP) indicates that prolonged treatment can increase both the 
proportions of patients with CRR of VA and the magnitude of the recovery 
observed. Furthermore, data from the RHODOS and from the EAP provide 
evidence that the LHON-causative mutation harboured is prognostic of 
CRR in VA. Therefore, secondary objectives of this study are to provide 
information on the effect of treatment duration on both the proportions of 
patients presenting with CRR and on the magnitude of any response with 
increasing treatment time and on the influence of the mutation harboured 
on CRR rate compared to spontaneous CRR (sCRR) in untreated control 
patients.  
 
The study will also allow the assessment of the safety and tolerability of 
long-term treatment with idebenone, with particular emphasis on the 
proportion of patients experiencing elevated Liver Function Tests (LFTs) or 
changes in blood cell counts. 
Number of Centres 
Approximately 35 
Multinational study with US sites operating under IND and EU sites not 
operating under IND. 
Number of Patients 
80 patients presenting ≤1 year after the onset of symptoms will be enrolled 
to ensure 61 provide VA assessments following 12 months of idebenone 
treatment (primary endpoint). 
 
80 patients presenting >1 year after the onset of symptoms will be enrolled 
to ensure 61 provide VA assessments following 12 months of idebenone 
treatment (secondary endpoint). Patients will be stratified according to time 
since onset of symptoms with a maximum of 30 patients to be enrolled in 
any of the strata of >1 - ≤2 years, >2 - ≤3 years, >3 - ≤4 years and >4 - ≤5 
years since onset of symptoms. 
Inclusion Criteria 
1. Impaired visual acuity in affected eyes due to LHON  
2. No explanation for visual loss besides LHON  
3. Age  12 years 
4. Onset of symptoms ≤5 years prior to Baseline 
5. Confirmation of either G11778A, G3460A or T14484C LHON mtDNA 
(for the ITT population, not required for enrolment) 
6. Written informed consent obtained from the patient 
7. Ability and willingness to comply with study procedures and visits 
8. Women of Childbearing Potential (WCBP) who have a negative urine 
or serum pregnancy test at Baseline visit and who are willing to use a 
highly effective contraceptive measure and maintain it until treatment 
discontinuation. 
Exclusion Criteria 
1. Patient has provided natural history data to the Case Record Survey 
(SNT-CRS-002) 
2. Any previous use of idebenone 
3. Any other cause visual impairment (e.g. glaucoma, diabetic 
retinopathy, AIDS related visual impairment, cataract, macular 
degeneration, etc.) or any active ocular disorder (uveitis, infections, 
inflammatory retinal disease, thyroid eye disease, etc.)  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 8 of 50 
 
4. Known history of clinically significant elevations (greater than 3 times 
the upper limit of normal) of AST, ALT or creatinine 
5. Patient has a condition or is in a situation which, in an investigator’s 
opinion may put the patient at significant risk, may confound study 
results or may interfere significantly with the patient’s participation in 
the study 
6. Participation in another clinical trial of any investigational drug within 3 
months prior to Baseline 
7. Hypersensitivity to the active substance or to any of the following 
excipients: 
Lactose 
monohydrate, 
Microcrystalline 
cellulose, 
Croscarmellose sodium, Povidone K25, Magnesium stearate, Colloidal 
silica, Macrogol 3350, Poly(vinyl alcohol), Talc, Titanium dioxide, 
Sunset yellow FCF (E110). 
8. Women who are pregnant or have a positive pregnancy test at Baseline 
visit 
9. Women who are breastfeeding. 
Treatment Period 
24 months 
Study Design 
Multicenter, interventional, open label study with external historical control 
group 
Efficacy Assessments 
Efficacy will be assessed at every visit by performing a VA test (logMAR). 
Safety Evaluations 
Safety will be assessed at every visit by evaluation of adverse events, and 
clinical laboratory evaluation of hematological and biochemical parameters 
(blood and urine samples).  
Study Procedures 
The study will be described to potentially eligible patients and Informed 
Consent will be obtained from the patient and/or parents/legal guardian 
prior to any study specific procedures being undertaken. 
There will be no screening visit for this study. Potential study participants 
will be assessed for eligibility of enrolment at Visit 1/Baseline.  
At Visit 1/Baseline: patient is informed about the trial and its procedures. 
Patient signs informed consent. Should the patient require additional time 
to consider participation in the trial, then a second Visit1/Baseline visit 
might be arranged. 
Study specific procedures will only be performed after the patient has 
signed the informed consent. 
The demographic characteristics will be collected. The medical history will 
be assessed and LHON diagnosis confirmed.  
Patients meeting inclusion/exclusion criteria and having signed the 
informed consent will be enrolled in the study. Enrolment failures and 
reasons thereof will be recorded in the CRF. 
In the absence of a genetic confirmation of the LHON mtDNA mutation, a 
blood sample will be taken for genetic testing. Should the genetic diagnosis 
reveal that a patient does not harbour a LHON-specific mtDNA mutation, 
the patient will be withdrawn from the study. 
It should be noted however that the VA outcomes for patients carrying one 
of the three major LHON-specific mtDNA mutations (G3460A, G11778A or 
T14484A) will be used in the primary analyses. 
 
Physical examination including height and weight, vital signs, and 
fundoscopic exam and visual acuity tests will be performed. Blood and 
urine samples and concomitant medication will be recorded.  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 9 of 50 
 
Urine or serum pregnancy test will be taken for WCBP. 
The investigator will dispense a patient diary and sufficient study 
medication to last until the next visit and instruct the patients carefully in 
their use.  
Results from blood and urine test must be available before the patient starts 
taking study medication. The patient will be informed by the investigator or 
study nurse by phone should these results not be available at the day of 
Visit 1/Baseline. 
The patient will take the first dose of study medication on Day 1 or the day 
the patient is informed to start study medication intake, whichever is 
applicable. The data of first dose of study medication intake is to be 
recorded in the patient diary. 
The study subject will continue the daily recordings in the patient diary to 
be completed throughout the entire study period. 
At Visit 2/Month 1: VA test will be performed. Blood and urine samples will 
be taken and the patient diary will be reviewed to assess the compliance, 
adverse events and concomitant medication.  
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated. 
The investigator will dispense a new patient diary and sufficient study 
medication to last until the next visit. 
At Visit 3/Month 3: VA test will be performed. Blood and urine samples will 
be taken and the patient diary will be reviewed to assess the compliance, 
adverse events and concomitant medication. 
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated. 
The investigator will dispense a new patient diary and sufficient study 
medication to last until the next visit. 
At Visit 4/Month 6: physical examination, vital signs and visual acuity tests 
will be performed. Blood and urine samples will be taken. The patient diary 
will be reviewed to assess the compliance, adverse events and 
concomitant medication.  
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated. 
The investigator will dispense a new patient diary and sufficient study 
medication to last until the next visit. 
At Visit 5/Month 9: visual acuity test will be performed. Blood and urine 
samples will be taken and the patient diary will be reviewed to assess the 
compliance, adverse events and concomitant medication. 
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated. 
The investigator will dispense a new patient diary and sufficient study 
medication to last until the next visit. 
At Visit 6/Month 12: physical examination, vital signs, fundoscopic exam 
and visual acuity tests will be performed. Blood and urine samples will be 
taken.  
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated.  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 10 of 50 
 
The investigator will dispense a new patient diary and sufficient study 
medication to last until the next visit. 
At Visit 7/Month 18: physical examination, vital signs and visual acuity 
tests will be performed. Blood and urine samples will be taken and the 
patient diary will be reviewed to assess the compliance, adverse events 
and concomitant medication.  
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated. 
The investigator will dispense a new patient diary and sufficient study 
medication to last until the next visit. 
At Visit 8/Month 24: physical examination, vital signs, fundoscopic exam 
and visual acuity tests will be performed. Blood and urine samples will be 
taken.  
A urine or serum pregnancy test will be performed for WCBP when clinically 
indicated. 
The investigator will dispense a new patient diary. No further study 
medication will be dispensed. 
At Visit 9, 28-35 days after drug discontinuation, a visual acuity test will be 
performed. Blood and urine samples will be taken and the patient diary will 
be collected and reviewed to assess adverse events and concomitant 
medication. A fundoscopic exam may be performed if abnormalities were 
observed at the previous visit. 
The patient will be informed that he/she completed the study. 
Statistical Methods 
Analysis Methods: 
The VA outcomes for patients treated with idebenone ≤1 year after onset of 
symptoms will be compared to a matching external untreated natural 
history control group. The primary endpoint will be analysed using a logistic 
regression model. The binary response will be used as the dependent 
variable. The independent variables include the treatment group 
(idebenone treated patients versus untreated control group) and mutation 
(G11778A, G3460A, T14484C). All patients who have at least one post-
baseline assessment at 12±3 months after Baseline will be included in the 
primary analysis. A sensitivity analysis assessing the impact of incomplete 
data will be performed with a generalized linear mixed model. 
The VA outcomes for patients treated with idebenone >1 year after onset 
of symptoms will be compared to the natural history outcomes from 
untreated external control patients and to the VA outcomes for patients 
treated with idebenone ≤1 year after onset of symptoms.  
 
Safety data will be analysed using descriptive statistics. 
 
A detailed description of the statistical analysis methods will be provided in 
the Statistical Analysis Plan which will be finalized before database lock. 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 11 of 50 
 
Study Flow Chart 
Visits/Contacts: 
 
 
  
 
 
 
 
Visit 1 / Baseline 
Day 1 
 
Informed Consent 
 
Medical History and confirmation of LHON 
 
Demographic characteristics 
 
Confirmation of Inclusion/Exclusion criteria 
 
Trial enrolment 
 
Confirmation of LHON mtDNA mutation (or blood sample for 
genetic test) 
 
Physical Examination (including height and weight) 
 
Vital Signs  
 
Fundoscopic Exam  
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP 
 
Concomitant Medication 
 
Distribution of Study Medication  
 
Distribution of Patient Diary  
 
 
 
Visit 2 / Month 1 
(+ 1 week) 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection and Distribution of Study Medication  
 
 
 
Visit 3 / Month 3 
(+ 1 week) 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection and Distribution of Study Medication  
 
 
 
Visit 4 / Month 6 
(+ 1 week) 
 
Physical Examination 
 
Vital Signs 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection and Distribution of Study Medication  
 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 12 of 50 
 
Visit 5 / Month 9 
(+ 1 week) 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection and Distribution of Study Medication  
 
 
 
Visit 6 / Month 12 
(+ 1 week) 
 
Physical Examination 
 
Vital Signs 
 
Fundoscopic Exam 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection and Distribution of Study Medication  
 
 
 
Visit 7 / Month 18 
(+ 1 week) 
 
Physical Examination 
 
Vital Signs 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection and Distribution of Study Medication  
 
 
 
Visit 8 / Month 24 
(+ 1 week) 
 
Physical Examination 
 
Vital Signs 
 
Fundoscopic Exam 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Urine or serum pregnancy test for WCBP when clinically 
indicated. 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Patient Compliance 
 
Collection and Distribution of Patient Diary  
 
Collection of Study Medication 
 
 
 
Visit 9 / Follow Up Visit 
(28-35 Days after  
drug discontinuation) 
 
 
Fundoscopic Exam (Optional) 
 
Visual Acuity (logMAR) 
 
Safety Blood and Urine samples 
 
Assessment of Adverse Events 
 
Concomitant Medication 
 
Collection of Patient Diary  
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 13 of 50 
 
Table of Contents 
Study Administrative Structure .................................................................................. 2 
Synopsis....................................................................................................................... 5 
Study Flow Chart ....................................................................................................... 11 
Table of Contents ...................................................................................................... 13 
Amendment History .................................................................................................. 16 
List of Abbreviations ................................................................................................. 17 
1 
Introduction ......................................................................................................... 18 
1.1 
Background................................................................................................................................... 18 
1.2 
Rationale for the Study ................................................................................................................. 18 
2 
Study Objectives and Endpoints ....................................................................... 20 
2.1 
Study Objectives ........................................................................................................................... 20 
2.1.1 
Primary Objective ................................................................................................................. 20 
2.1.2 
Secondary Objectives ........................................................................................................... 20 
2.2 
Study Endpoints ........................................................................................................................... 20 
2.2.1 
Primary Endpoint .................................................................................................................. 20 
2.2.2 
Secondary Endpoints ........................................................................................................... 20 
3 
Study Design ....................................................................................................... 21 
3.1 
Summary of Study Design ............................................................................................................ 21 
3.2 
Trial Treatment, Dosage and Regimen ........................................................................................ 21 
3.3 
Duration of Subject Participation .................................................................................................. 21 
4 
Selection of Subjects .......................................................................................... 22 
4.1 
Inclusion Criteria ........................................................................................................................... 22 
4.2 
Exclusion Criteria .......................................................................................................................... 22 
4.3 
Life Style Guidelines ..................................................................................................................... 22 
4.4 
Pregnancy and lactation ............................................................................................................... 23 
5 
Study Medication and Administration ............................................................... 23 
5.1 
Drug Supplies ............................................................................................................................... 23 
5.1.1 
Formulations ......................................................................................................................... 23 
5.1.2 
Packaging and Labelling ...................................................................................................... 23 
5.1.3 
Supplies ................................................................................................................................ 23 
5.1.4 
Storage ................................................................................................................................. 23 
5.2 
Dosage and Administration .......................................................................................................... 24 
5.3 
Treatment ..................................................................................................................................... 24 
5.4 
Replacement of Unusable Study Medication ............................................................................... 24 
5.5 
Method of Blinding / Breaking the Blind ....................................................................................... 24 
5.6 
Compliance and Accountability .................................................................................................... 24 
5.7 
Site Accountability of Study Drug ................................................................................................. 24 
5.8 
Return or Destruction of Study Medication ................................................................................... 24 
6 
Conduct of Study ................................................................................................ 25 
6.1 
Outline of Study Procedures......................................................................................................... 25 
6.2 
Schedule of Assessments ............................................................................................................ 27 
6.2.1 
Visit 1 / Baseline (Day 1) ...................................................................................................... 28 
6.2.2 
Visit 2 / Month 1 (± 1 week) .................................................................................................. 28 
6.2.3 
Visit 3 / Month 3 (± 1 week) .................................................................................................. 28 
6.2.4 
Visit 4 / Month 6 (± 1 week) .................................................................................................. 28 
6.2.5 
Visit 5 / Month 9 (± 1 week) .................................................................................................. 29 
6.2.6 
Visit 6 / Month 12 (± 1 week) ................................................................................................ 29 
6.2.7 
Visit 7 / Month 18 (± 1 week) ................................................................................................ 29 
6.2.8 
Visit 8 / Month 24 (± 1 week) ................................................................................................ 29 
6.2.9 
Visit 9 / Follow-Up Visit (28-35 days after study drug discontinuation) ................................ 30 
6.3 
Concomitant Medication / Treatment ........................................................................................... 30 
6.3.1 
Prohibited Concomitant Medication ...................................................................................... 30 
6.3.2 
Interaction with other medicinal products ............................................................................. 30 
6.4 
Study Completion ......................................................................................................................... 30 
6.5 
Discontinuation / Withdrawal ........................................................................................................ 31 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 14 of 50 
 
6.5.1 
Conditions for discontinuation/withdrawal ............................................................................ 31 
6.5.2 
Procedures for Handling Discontinued Patients ................................................................... 31 
6.6 
Treatment and Storage of Biological Samples ............................................................................. 31 
6.6.1 
Safety Blood and Urine Samples .......................................................................................... 31 
7 
Efficacy Assessments ........................................................................................ 32 
7.1 
Visual acuity.................................................................................................................................. 32 
8 
Safety Evaluations .............................................................................................. 32 
8.1 
Adverse Events (AEs) .................................................................................................................. 32 
8.1.1 
Definition of an Adverse Event ............................................................................................. 32 
8.1.2 
Adverse Events of Special Interest (AESI) ........................................................................... 33 
8.1.3 
Surveillance Period for Occurrence of Adverse Events ....................................................... 33 
8.1.4 
Recording Adverse Events ................................................................................................... 33 
8.1.5 
Assessment of Severity ........................................................................................................ 34 
8.1.6 
Assessment of Causality ...................................................................................................... 34 
8.1.7 
Follow-up of Adverse Events and Assessment of Outcome ................................................ 35 
8.2 
Serious Adverse Events ............................................................................................................... 35 
8.2.1 
Definition of a Serious Adverse Event .................................................................................. 35 
8.2.2 
Reporting Serious Adverse Events and AESIs .................................................................... 36 
8.2.3 
Causality Assessment of Serious Adverse Events ............................................................... 37 
8.2.4 
Follow-up of Serious Adverse Events .................................................................................. 37 
8.3 
Treatment of Adverse Events ....................................................................................................... 37 
8.4 
Pregnancy ..................................................................................................................................... 37 
8.5 
Anthropometric measurements .................................................................................................... 38 
8.5.1 
Weight and height (Visit 1 only) ............................................................................................ 38 
8.6 
Safety and Monitoring Measures .................................................................................................. 38 
8.6.1 
Physical Examination and Vital Signs .................................................................................. 38 
8.6.2 
Fundoscopic Exam ............................................................................................................... 38 
8.6.3 
Safety Blood Sampling and Urine Analysis .......................................................................... 38 
8.6.4 
Highly effective contraceptive measures .............................................................................. 39 
8.7 
Data Safety Monitoring Board (DSMB) ........................................................................................ 39 
9 
Data Evaluation and Statistics ........................................................................... 40 
9.1 
General Considerations ................................................................................................................ 40 
9.2 
Analysis Variables ........................................................................................................................ 40 
9.2.1 
Primary Endpoint .................................................................................................................. 40 
9.2.2 
Secondary Endpoints ........................................................................................................... 42 
9.2.3 
Safety Variables.................................................................................................................... 43 
9.3 
Analysis Populations .................................................................................................................... 43 
9.3.1 
Intent-To-Treat Population .................................................................................................... 43 
9.3.2 
Safety Population.................................................................................................................. 43 
9.4 
Analysis Methods ......................................................................................................................... 43 
9.4.1 
Analysis of Demographic and Baseline Characteristics ....................................................... 43 
9.4.2 
Efficacy Evaluation ............................................................................................................... 43 
9.4.3 
Safety Evaluation .................................................................................................................. 44 
9.5 
Analyses ....................................................................................................................................... 44 
9.6 
Sample Size and Power Considerations ...................................................................................... 44 
9.7 
Quality Assurance of Data ............................................................................................................ 45 
10 
Ethics, Regulatory and Administrative Considerations ............................... 45 
10.1 
Institutional Review Board (IRB) / Independent Ethics Committee (IEC)..................................... 45 
10.2 
Authorities ..................................................................................................................................... 46 
10.3 
Patient Information and Informed Consent ................................................................................... 46 
10.4 
Monitoring ..................................................................................................................................... 46 
10.5 
Audit and Inspection ..................................................................................................................... 47 
10.6 
Source Documents ....................................................................................................................... 47 
10.7 
Data Protection ............................................................................................................................. 47 
10.8 
Case Report Forms ...................................................................................................................... 47 
10.9 
Investigator Site File ..................................................................................................................... 48 
10.10 
Premature Termination of the Study ........................................................................................ 48 
10.11 
Clinical Study Report ................................................................................................................ 48 
10.12 
Patient Insurance and Indemnity .............................................................................................. 48 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 15 of 50 
 
10.13 
Amendments to the Protocol .................................................................................................... 48 
10.14 
Disclosure of Information .......................................................................................................... 49 
10.15 
Definition of End of Study ......................................................................................................... 49 
10.16 
Publication and Presentation Policy ......................................................................................... 49 
10.17 
Archiving and Data Retention ................................................................................................... 49 
10.18 
Registration of the Clinical Trial in a Publicly Accessible Database ......................................... 49 
11 
References ....................................................................................................... 50 
 
 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 16 of 50 
 
Amendment History 
 
Amendment 1 (6 March 2019 
 
1. Amendment to Study Administrative Structure to update study team after changes at 
Santhera and change of CRO name.  
 
2. Amendment to Signature page after change in protocol signature process and changes 
in the study team. 
 
3. Amendment to section 1.1 and section 11 to update percentage of individuals with LHON 
that harbour one of three point mutations in mitochondrial DNA to more than 90%. 
 
4. Amendment to section 4.4 and 11 to clarify that the reference guideline on contraception 
for this trial is the Clinical Trial Facilitation Group Guidance on contraception 2014. 
 
5. Amendment to section 6.2 to correct an inconsistency in the footnote. 
 
6. Amendment to section 6.3.2 to update information on interaction with other medicinal 
products. 
 
7. Amendment to section 8.1.2 to add guidance on the definition and reporting of Adverse 
Events of Special Interest (AESI). 
 
8. Amendment to section 8.1.6 and 8.2.3 to clarify the definition of related/unrelated AE and 
SAEs. 
 
9. Amendment to section 9.3.1 to better define the Intent-To-Treat population. 
 
10. Amendment to section 9.5 and synopsis to update timelines on the preparation of the 
statistical analysis plan. 
 
11. Amendment to section 3.1, 3.2 and 9.6 and synopsis to update the number of patients to 
be enrolled to the LEROS study based on sample size re-calculation. 
 
12. Amendment to section 10.1 to clarify the notification of Urgent Safety Measures by the 
Investigator to the Sponsor and IRB/IEC. 
 
13. Amendment to section 10.4 to clarify that Quality Risk Assessment for the trial will be 
performed according to Santhera SOPs. 
 
14. Amendment to section 10 to add section 10.18 referring to the registration of the Clinical 
Trial in a Publicly Accessible Database. 
 
15. Minor editorial changes. 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 17 of 50 
 
List of Abbreviations 
 
 
 
AE(s) 
Adverse Event(s) 
ALT 
Alanine aminotransferase 
AST 
Aspartate aminotransferase  
CF 
Counting Fingers 
CFR 
Code of Federal Regulations 
CHMP 
CK 
Committee on Human Medicinal Products 
Creatine Kinase 
CRF 
Case Report Form 
CRR 
Clinically relevant recovery (of visual acuity) 
CRS 
DoB 
DSMB 
Case Record Survey 
Date of Birth 
Data Safety Monitoring Board 
EAP 
EDC 
Expanded Access Program 
Electronic Data Capture 
GCP 
Good Clinical Practices 
GGT 
Gamma-Glutamyl Transferase 
HM 
Hand Motion  
IB 
Investigator’s Brochure 
ICH 
International Conference on Harmonisation 
IEC/IRB 
Independent Ethics Committee/Institutional Review Board 
ITT 
IUD 
IUS 
Intent-to-Treat 
Intrauterine device  
Intrauterine hormone-releasing system 
LFT 
Liver Function Test 
LHON 
Leber’s Hereditary Optic Neuropathy 
logMAR 
Logarithm of the Minimum Angle of Resolution 
LP 
Light Perception 
mtDNA 
Mitochondrial Deoxyribonucleic acid 
MMRM 
Mixed Model for Repeated Measures 
OLS 
PP 
Open Label Study 
Per-Protocol 
ROS 
Reactive Oxygen Species 
SAE(s) 
Serious Adverse Event(s) 
SAP 
Statistical Analysis Plan 
sCRR 
Spontaneous Clinically Relevant Recovery 
VA 
WCBP 
Visual Acuity 
Women of Childbearing Potential 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 18 of 50 
 
1 
Introduction 
1.1 
Background 
Leber’s Hereditary Optic Neuropathy 
LHON is a maternally inherited loss of vision due to atrophy of the optic nerve. More than 90% 
of individuals with LHON harbour one of three point mutations in mitochondrial DNA (mtDNA) 
(G11778A, T14484C, G3460A) affecting genes encoding complex I subunits of the respiratory 
chain (Mackey 1996, Newman 2013). It typically presents in young adults, mostly men, as 
painless acute or subacute visual failure of both eyes in quick succession. The estimated 
prevalence is approximately 2.2 per 100,000 (Mascialino et al., 2012) and LHON is thus an 
Orphan Disease according to EU and US criteria. Clinically, the acute phase of the disease 
begins with blurring of central vision and colour de-saturation that affect both eyes. After the 
initial symptoms, both eyes are usually affected within two to four months from disease onset. 
Within 12 months of visual loss in one eye, over 97% of patients will have second eye 
involvement. The central visual acuity deteriorates to the level of counting fingers in up to 80% 
of cases. Following the nadir, acuity may improve. The degree of improvement is dependent, in 
part, also on the precise genetic mutation of affected patients. With disease progression, 
individuals then proceed into the atrophic phase and are usually legally blind for the rest of their 
lives with a permanent large centrocecal scotoma (Sadun et al., 2011).  
Idebenone 
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-cyclohexa-2,5-diene-1,4-dione 
has 
been suggested to be effective in by-passing the complex I deficiency resulting from the mtDNA 
point mutations and maintaining cellular energy production by stimulating the alternative 
pathway through complexes II and III (Haefeli et al., 2011). This activity may also reduce the 
production of reactive oxygen species (ROS) associated with complex I deficiency and to protect 
cell membranes and mitochondria from oxidative damage. This provides a strong rationale for 
its use in LHON (summarized in Gueven and Faldu, 2013; Gueven, 2014).  
Detailed information on the medicinal product and on non-clinical data is available in the 
Investigator’s Brochure (IB). 
1.2 
Rationale for the Study 
The randomized, placebo-controlled RHODOS (SNT-II-003) trial (Klopstock et al., 2011), the 
retrospective cohort study of Carelli et al., (2011), Santhera’s ongoing Expanded Access 
Program (EAP) and several case reports (summarized in Gueven and Faldu, 2013), provide 
evidence that idebenone promotes the recovery of VA in patients with LHON. However, due to 
the nature of these datasets, this evidence is not considered comprehensive. 
In view of the urgent medical need and poor prognosis of LHON if untreated, a randomized, 
placebo-controlled study to provide comprehensive data is not considered feasible in LHON. An 
open-label study is therefore considered the most appropriate strategy for gathering additional 
evidence for the efficacy of idebenone in the treatment of LHON. The primary objective of this 
study is therefore to compare the outcomes for patients treated with idebenone ≤1 year of the 
onset of symptoms in this study with those of matching untreated patients from an external 
natural history control group generated in a historical case record survey (CRS). 
In RHODOS, LHON patients enrolling up to 5 years after the onset of symptoms of disease were 
treated with idebenone. Whilst natural history VA outcomes data collected from LHON patients 
early in the course of the disease is available, relatively little reliable natural history VA outcomes 
data is available from patients with longer disease durations. The primary endpoint of this study 
will therefore compare the VA outcomes for patients treated with idebenone ≤1 year of the onset 
of symptoms with matching natural history control data. Secondary endpoints will include 
outcomes for patients treated with idebenone >1 year after the onset of symptoms. Since LHON 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 19 of 50 
 
is known to lead to the apoptotic loss of retinal ganglion cells where the extent of loss increases 
with time since onset of disease, this study will explore further the relationship between time 
since onset at the initiation of idebenone therapy and CRR, where possible compared to 
untreated control patients. 
The treatment duration in RHODOS was 6 months and a larger proportion of idebenone-treated 
patients presented with CRR in VA compared to placebo. However, data from Santhera’s 
ongoing Expanded Access Program (EAP) indicates that prolonged treatment can increase both 
the proportions of patients with CRR of VA and the magnitude of the recovery observed.  
Proportions of Patients and Eyes in the EAP with CRR from VA Nadir following 6 months and 12 months of 
treatment 
 
Magnitude of Recovery in Eyes in the EAP with CRR from VA Nadir at the 6 month, 12 month or at the last 
observation 
 
Furthermore, data from the RHODOS and from the EAP provide evidence that the LHON-
causative mutation harboured is prognostic of CRR in VA.  
Therefore, secondary objectives of this study are to provide information on the effect of treatment 
duration on both the proportions of patients presenting with CRR and on the magnitude of any 
response with increasing treatment time and on the influence of the mutation harboured on CRR 
rate compared to spontaneous CRR (sCRR) untreated control patients.  
The study will also allow the assessment of the safety and tolerability of long-term treatment with 
idebenone, with particular emphasis on the proportion of patients experiencing elevated Liver 
Function Tests (LFTs) or changes in blood cell counts. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 20 of 50 
 
2 
Study Objectives and Endpoints 
2.1 
Study Objectives 
2.1.1 
Primary Objective 
 
To assess efficacy of idebenone in the promotion of recovery or stabilization of visual acuity 
in patients treated with idebenone ≤1 year after the onset of symptoms, compared to an 
external natural history control group of idebenone naïve patients 
2.1.2 
Secondary Objectives 
 
To assess efficacy of idebenone in the promotion of recovery or stabilization of vision in 
LHON patients treated with idebenone >1 year after the onset of symptoms, compared to an 
external natural history control group of idebenone naive patients 
 
To compare the promotion of recovery or stabilization of visual acuity in LHON patients 
treated with idebenone ≤1 and >1 year after the onset of symptoms  
 
To assess the influence of mutation on the promotion of recovery or stabilization of visual 
acuity in LHON patients treated with idebenone  
 
To assess the influence of time since onset of symptoms prior to the initiation of treatment 
with idebenone on the promotion of recovery or stabilization of visual acuity in LHON patients 
 
To assess the influence of duration of treatment with idebenone on changes in visual acuity 
in LHON patients 
 
To assess safety of long-term treatment of LHON patients with idebenone. 
2.2 
Study Endpoints 
2.2.1 
Primary Endpoint 
 
Proportion of eyes with clinically relevant recovery of VA from Baseline or in which Baseline 
VA better than 1.0 logMAR was maintained at Month 12 in patients treated with idebenone 
≤1 year after the onset of symptoms, compared to matching external natural history control 
group  
 
Clinically Relevant Recovery (CRR) is defined as a change from “off-chart” visual acuity (VA) to 
at least 1.6 logMAR value or an improvement of at least 0.2 logMAR value within “on-chart”. 
2.2.2 
Secondary Endpoints 
 
Components of the primary endpoint: 
- 
Proportion of eyes with CRR of VA from Baseline at Month 12 compared to matching 
external natural history control group 
- 
Proportion of eyes in which Baseline VA better than 1.0 logMAR was maintained at 
Month 12 compared to matching external natural history control group. 
 
Proportion of eyes in patients treated with idebenone >1 year after the onset of symptoms 
with CRR of VA from Baseline or in which Baseline VA better than 1.0 logMAR was 
maintained at Month 12 compared to external natural history control group, in all patients 
and classified by mutation 
 
Proportion of eyes and patients treated with idebenone ≤1 year after the onset of symptoms 
with CRR of VA from Baseline or in which Baseline visual acuity better than 1.0 logMAR was 
maintained following 6, 18 and 24 months of treatment with idebenone compared to matching 
external natural history control group, in all patients and classified by mutation 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 21 of 50 
 
 
Proportion of eyes/patients treated with idebenone ≤1 year or >1 year after the onset of 
symptoms with “Off-chart” VA at Baseline in whom VA improves to better than 1.60 logMAR 
by Month 6, 12, 18 and 24  
 
Proportion of eyes/patients treated with idebenone ≤1 year or >1 year after the onset of 
symptoms with VA in the categories of better than 1.0 logMAR, 1.0 to 1.68 logMAR and 
above 1.68 logMAR at each assessment time point up to Month 24 
 
Safety as assessed by AE count and laboratory analyses during the study 
3 
Study Design 
3.1 
Summary of Study Design 
The study will be an open-label interventional study requiring 80 patients enrolled ≤1 year after 
the onset of symptoms to complete the 12 month treatment period (for evaluation of the primary 
endpoint), and 80 patients enrolled >1 year after the onset of symptoms to complete the 12 
month treatment period (for evaluation of the secondary endpoints in these patients). 
 
This multinational study is conducted with one protocol for sites under the IND (U.S. sites) in 
compliance with the IND requirements contained in 21 CFR 312, and a different version of the 
protocol for foreign sites not under the IND. As the intent is to pool the data from U.S. and foreign 
sites, it is ensured, as required, that the protocol versions are very similar or identical. 
 
Patient eligibility for enrolment will be determined during the Baseline (Visit 1). Beginning at 
Baseline (Visit 1), the patient will receive study medication to take at home and will undergo 
regular assessments in the clinic throughout the study period until Visit 8 (Month 24) at which 
time the study medication is withdrawn. For all patients, there will be a final follow-up 28-35 days 
after study medication withdrawal. Patients enrolled in the study will commence study medication 
intake on the first day after the Baseline visit. 
3.2 
Trial Treatment, Dosage and Regimen 
Enrolled patients will  receive idebenone 900 mg/day (2 x 150 mg tablets to be taken orally 3 
times daily with meals) according to the IB. 
3.3 
Duration of Subject Participation 
Patient’s participation will last approximately 25 months: 24-month treatment phase and an 
approximately 1 month follow-up phase.  
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 22 of 50 
 
4 
Selection of Subjects 
4.1 
Inclusion Criteria 
The following criteria should be assessed during Baseline Visit. If any does not apply, the patient 
must not be included in the study: 
1. 
Impaired visual acuity in affected eyes due to LHON  
2. 
No explanation for visual loss besides LHON  
3. 
Age  12 years 
4. 
Onset of symptoms ≤5 years prior to Baseline 
5. 
Confirmation of either G11778A, G3460A or T14484C LHON mtDNA (for the ITT population, 
not required for enrolment) 
6. 
Written informed consent obtained from the patient 
7. 
Ability and willingness to comply with study procedures and visits 
8. 
Women of Childbearing Potential (WCBP) who have a negative urine or serum pregnancy 
test at Baseline visit and who are willing to use a highly effective contraceptive measure and 
maintain it until treatment discontinuation. 
4.2 
Exclusion Criteria 
The following criteria should be checked during Baseline Visit. If any applies, the patient must 
not be included in the study: 
1. 
Patient has provided natural history data to the Case Record Survey (SNT-CRS-002) 
2. 
Any previous use of idebenone 
3. 
Any other cause of visual impairment (e.g. glaucoma, diabetic retinopathy, AIDS related 
visual impairment, cataract, macular degeneration, etc.) or any active ocular disorder 
(uveitis, infections, inflammatory retinal disease, thyroid eye disease, etc.)  
4. 
Known history of clinically significant elevations (greater than 3 times the upper limit of 
normal) of AST, ALT or creatinine 
5. 
Patient has a condition or is in a situation which, in an investigator’s opinion may put the 
patient at significant risk, may confound study results or may interfere significantly with the 
patient’s participation in the study 
6. 
Participation in another clinical trial of any investigational drug within 3 months prior to 
Baseline 
7. 
Hypersensitivity to the active substance or to any of the following excipients: Lactose 
monohydrate, Microcrystalline cellulose, Croscarmellose sodium, Povidone K25, 
Magnesium stearate, Colloidal silica, Macrogol 3350, Poly(vinyl alcohol), Talc, Titanium 
dioxide, Sunset yellow FCF (E110).  
8. 
Women who are pregnant or have a positive pregnancy test at Baseline visit 
9. 
Women who are breastfeeding 
4.3 
Life Style Guidelines  
With the exception of the criteria described in section 4.4, there are no particular lifestyle 
recommendations. However all smoking patients will be advised that smoking is a special risk 
factor for LHON and will be counselled by the investigator regarding smoking cessation.  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 23 of 50 
 
4.4 
Pregnancy and lactation 
Although animal studies do not indicate direct or indirect harmful effects with respect to 
reproductive toxicity, women who are pregnant or have a positive pregnancy test at Baseline 
visit and women who are breastfeeding will be excluded from the study. 
For women who are breastfeeding, a decision must be taken to discontinue breastfeeding or be 
excluded from the study. 
Furthermore, WCBP can be included in the study if they have a negative urine or serum 
pregnancy test at Baseline visit and are willing to use a highly effective contraceptive measure 
and maintain it until treatment discontinuation. 
The Clinical Trial Facilitation Group recommendations should be taken into account as guidance 
for the contraception methods to be used for WCBP enrolled in this trial (see also section 8.6.4). 
 
5 
Study Medication and Administration 
5.1 
Drug Supplies 
The study medication must not be used for any purpose other than that described in this protocol. 
5.1.1 
Formulations 
Idebenone is developed and manufactured by Santhera Pharmaceuticals (Switzerland) Ltd. and 
will be provided as 150 mg film-coated tablets. 
Ingredients: idebenone, Lactose Monohydrate, Microcrystalline Cellulose, Croscarmellose 
Sodium, Povidone (k = 25), Magnesium Stearate, Colloidal silica, Coating (Macrogol/PEG 3350, 
Polyvinylalkohol, Titanium Dioxide, Talc, Sunset yellow FCF (E110)). 
5.1.2 
Packaging and Labelling 
The study medication will be provided in bottles with 180 tablets.  
Patients will receive study medication at Visit 1 through Visit 7. Patients will receive 2 bottles at 
Visit 1, 3 bottles at Visit 2, 4 bottles at Visits 3 through Visit 5 and 7 bottles at Visit 6 and Visit 7. 
Each bottle contains 180 tablets, the medication for 30 days. Up to 31 bottles will be assigned 
to each patient. 
The labelling encompasses the information according to GMP guideline Volume 4, Annex 13 for 
Investigational Products and the local laws and 21 CFR Section 312.6 – Labelling of an 
investigational new drug.  
5.1.3 
Supplies 
The sponsor will supply the investigator with enough study medication to administer sufficient 
doses to all patients as described in the present protocol. Additional material will be supplied for 
replacement in case of damage or inappropriate storage conditions. All medication needs to be 
accounted for on the form provided. 
Under no circumstances is it permitted to use the study medication for purposes other than those 
specified in this protocol. 
5.1.4 
Storage 
Investigators must store study medication in a safe, controlled place with no access for 
unauthorized personnel. Study medication must be stored under the conditions shown in the 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 24 of 50 
 
label. Study medication will be stored at the study site or pharmacy according to legal 
requirements. 
Investigators will provide patients with instructions on how to use and store medication at home. 
5.2 
Dosage and Administration 
Patients are dispensed enough medication to last until the next scheduled visit. All patients will 
be instructed to take study medication as follows: 
 
2 tablets 3 times daily with meals, totalling 6 tablets a day 
Patients will document in the patient diary, on a daily basis, the medication they have taken.  
5.3 
Treatment  
All patients receive idebenone study drug at the same dose; there is no randomization process. 
5.4 
Replacement of Unusable Study Medication 
In addition to the materials for the planned number of patients, additional bottles will be supplied 
to replace any that are damaged or lost. The investigator should replace any lost/missing bottle 
with a replacement bottle. The sponsor need not be notified immediately in these cases. 
However, documentation of the use of the replacement bottle and reason for using it must be 
recorded by the investigator. 
If the patient loses any study medication, or finds that some medication is unusable, he/she must 
contact the investigator immediately. The investigator will replace the study medication as 
necessary, documenting the replacement, as above. 
5.5 
Method of Blinding / Breaking the Blind 
This is an open label study; no blinding implemented. 
5.6 
Compliance and Accountability 
Patients will document medication taken, on a daily basis, in the patient diary.  
At each visit, the patient will be asked to return all unused study medication and all bottles to the 
investigator. Medication will be inventoried and treatment compliance will be calculated as a 
percentage by dividing the number of tablets taken by the number of days since the previous 
visit multiplied by six, multiplied by 100. If the compliance lies outside of the range of 80-120%, 
inclusively, the sponsor must be consulted to decide whether or not the patient should continue 
in the study. 
5.7 
Site Accountability of Study Drug 
At any time the figures of supplied, used and remaining medication should match. At the end of 
the study, it must be possible to reconcile delivery records with those of used and unused stocks. 
Account must be given of any discrepancies. 
5.8 
Return or Destruction of Study Medication 
At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, 
and drug remaining. This reconciliation will be logged on the drug reconciliation form, signed 
and dated. Any discrepancies noted will be investigated, resolved and documented prior to 
return or destruction of unused study drug. Drug destroyed on site will be documented in the 
study files. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 25 of 50 
 
After approval from Santhera Pharmaceuticals (Switzerland) Ltd, unused study medication 
should be destroyed in accordance with the applicable local law and can either be returned to 
Santhera or destroyed at the investigational site. Documentation of destruction of the study drug 
must be forwarded to the sponsor. 
6 
Conduct of Study 
6.1 
Outline of Study Procedures 
All study procedures are outlined in the Schedule of Assessments shown below. A more detailed 
description of the study procedures performed at each visit is given in the following sections of 
the protocol. 
Patients will be enrolled to receive 900 mg idebenone (2 tablets 3 times daily with meals) for 24 
months. Starting with Baseline/Visit 1 sufficient study medication will be dispensed to last until 
the next visit. The patient will take the first dose of study medication on Day 1, the day of the 
Baseline Visit (or as instructed by the site investigator / study nurse). 
The duration of study participation for each individual patient will be approximately 25 months 
and comprise 9 study visits (V1-V9). Before any study-specific procedures are undertaken, the 
patient (and parent/legal guardian if required) will have been thoroughly informed by the 
investigator of the purpose of the study, the relevant procedures and of patient rights and 
responsibilities. Patient information will be distributed in writing and signatures of consent 
obtained on the consent form. (See also Section 10.3).  
Patient enrolled in the study will receive study medication at Baseline/Visit 1; the first study 
medication intake is on the day of the Baseline/Visit 1 (or as instructed by the site investigator / 
study nurse). During the 24 month treatment period, visits take place at Month 1, Month 3, Month 
6, Month 9, Month 12, Month 18 and Month 24. Visit 8 (Month 24) is the endpoint of treatment. 
Visit 9 is a follow-up, 28-35 days after study medication discontinuation. 
Physical examination and measurement of vital signs will be undertaken at Baseline/Visit 1 and 
then at Visit 4/Month 6, Visit 6/Month 12, Visit 7/Month 18 and Visit 8/Month 24. 
Safety blood and urine and safety assessments will be done at each visit. 
A urine or serum pregnancy test will be performed for WCBP at the baseline visit and further 
when clinically indicated. 
Assessment of VA (assessed by ETDRS charts and reported in logMAR value) will be done at 
every visit.  
During the Baseline visit the diagnosis of LHON will be confirmed and other eye diseases 
excluded. This will require fundoscopy with dilated pupils to be performed at the Baseline visit 
and every 12 months thereafter. Blood sample will be taken for the genetic analysis, if the genetic 
diagnosis of the patient is not confirmed at the Baseline visit. The report from the genetic analysis 
will need to be on file prior to Visit 4.  
Should the genetic diagnosis reveal that a patient does not harbour a LHON-specific mtDNA 
mutation, the patient will be withdrawn from the study. 
It should be noted however that the VA outcomes for patients carrying one of the three major 
LHON-specific mtDNA mutations (G3460A, G11778A or T14484A) will be used in the primary 
analyses. 
The following study procedures are performed at Baseline/Visit 1: physical exam, vital signs, 
weight, safety blood and urine sampling and a urine or serum pregnancy test for WCBP. The 
investigator should ensure that the results of the safety blood and urine analyses and pregnancy 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 26 of 50 
 
test are reviewed and approved during Visit 1. The patient will be informed by the investigator or 
study nurse by phone should these results not be available at the day of Visit 1/Baseline. 
Patients and/or parents/legal guardians will monitor safety throughout the study at home, and 
will document any adverse events (AEs), or other relevant findings in a patient diary. 
Patient and/or the parent/legal guardian will be instructed to contact the investigator immediately 
should the patient manifest any signs or symptoms perceived as serious during the period 
extending from the day of signature of the consent form up to and including the last visit. After 
this period of time, the investigator should report to the sponsor only AEs that are serious and 
considered related to the study medication. 
Information about AEs or serious adverse events (SAEs) will be collected throughout the study 
period and followed up as referred to in Sections 8.1 – 8.3 of this protocol. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 27 of 50 
 
6.2 
Schedule of Assessments   
 
Visit 1 / 
Baseline 
Day 1 
Visit 2 /  
Month 1  
(+ 1 week) 
Visit 3 /  
Month 3 
(+ 1 week) 
Visit 4 /  
Month 6 
(+ 1 week) 
Visit 5 /  
Month 9 
(+ 1 week) 
Visit 6 /  
Month 12 
(+ 1 week) 
Visit 7 /  
Month 18 
(+ 1 week) 
Visit 8 /  
Month 24 
(+ 1 week) 
Visit 9 /  
Follow-Up Visit 
(28-35 days after drug 
discontinuation) 
Informed Consent 
X 
 
 
 
 
 
 
 
 
Inclusion/Exclusion criteria  
X  
 
 
 
 
 
 
 
 
Genetic Analysis Blood Sampling 
X 
 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
Physical Exam, height & weight (V1 
only) 
X  
 
 
X 
 
X 
X 
X 
 
Vital Signs (1)  
X  
 
 
X 
 
X 
X 
X 
 
Urine or serum pregnancy test (for 
WCBP) 
X 
X (3)  
 
Safety Blood Sampling  
X  
X 
X 
X 
X 
X 
X 
X 
X 
Safety Urine Analysis 
X  
X 
X 
X 
X 
X 
X 
X 
X 
Fundoscopic Exam 
X 
 
 
 
 
X 
 
X 
X (optional) 
Visual Acuity (logMAR) 
X 
X 
X 
X 
X 
X 
X 
X 
X  
Adverse Events 
 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Distribution of Patient Diary 
X 
X 
X 
X 
X 
X 
X 
X 
 
Collection of Patient Diary 
 
X 
X 
X 
X 
X 
X 
X 
X 
Dispensing of Study Medication 
X (2) 
X 
X 
X 
X 
X 
X 
 
 
Collection of Residual Study Medication 
 
X 
X 
X 
X 
X 
X 
X 
 
Patient Compliance 
 
X 
X 
X 
X 
X 
X 
X 
 
End of Study 
 
 
 
 
 
 
 
 
X 
 (1) Heart rate and blood pressure in supine position, respiratory rate in supine position. 
 (2) First administration of study medication to be on Day 1 (day of Baseline visit or when approved by the investigator/study nurse). 
 (3) When clinically indicated.


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 28 of 50 
 
 
6.2.1 
Visit 1 / Baseline (Day 1) 
Baseline assessments include: 
Informed Consent 
Medical History and confirmation of LHON (blood sample for genetic testing) 
Demographic characteristics 
Inclusion/Exclusion criteria 
Physical Examination (including height & weight) 
Vital Signs  
Safety Blood analysis 
Safety Urine analysis 
Urine or serum pregnancy test for WCBP 
Fundoscopic Exam 
Visual Acuity (logMAR) 
Concomitant Medication 
Distribution of Study Medication  
Distribution of Patient Diary 
6.2.2 
Visit 2 / Month 1 (± 1 week) 
Assessments include: 
Safety Blood analysis 
Safety Urine analysis 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 
Concomitant Medication 
Patient Compliance 
Collection and Distribution of Study Medication  
Collection and Distribution of Patient Diary 
6.2.3 
Visit 3 / Month 3 (± 1 week)  
Assessments include: 
Safety Blood analysis 
Safety Urine analysis 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 
Concomitant Medication 
Patient compliance 
Collection and Distribution of Study Medication  
Collection and Distribution of Patient Diary 
6.2.4 
Visit 4 / Month 6 (± 1 week) 
Assessments include: 
Physical Examination 
Vital Signs 
Safety Blood analysis 
Safety Urine analysis 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 29 of 50 
 
Concomitant Medication 
Patient compliance 
Collection and Distribution of Study Medication  
Collection and Distribution of Patient Diary 
6.2.5 
Visit 5 / Month 9 (± 1 week) 
Assessments include: 
Safety Blood analysis 
Safety Urine analysis 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 
Concomitant Medication 
Patient compliance 
Collection and Distribution of Study Medication  
Collection and Distribution of Patient Diary 
6.2.6 
Visit 6 / Month 12 (± 1 week) 
Assessments include: 
Physical Examination 
Vital Signs 
Safety Blood analysis 
Safety Urine analysis 
Fundoscopic Exam 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 
Concomitant Medication 
Patient compliance 
Collection and Distribution of Study Medication  
Collection and Distribution of Patient Diary 
6.2.7 
Visit 7 / Month 18 (± 1 week) 
Assessments include: 
Physical Examination  
Vital Signs 
Safety Blood analysis 
Safety Urine analysis 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 
Concomitant Medication 
Patient compliance 
Collection and Distribution of Study Medication  
Collection and Distribution of Patient Diary 
6.2.8 
Visit 8 / Month 24 (± 1 week) 
Assessments include: 
Physical Examination 
Vital Signs 
Safety Blood analysis 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 30 of 50 
 
Safety Urine analysis 
Fundoscopic Exam 
Visual Acuity (logMAR) 
Urine or serum pregnancy test for WCBP when clinically indicated 
Assessment of Adverse Events 
Concomitant Medication 
Patient compliance 
Collection of Study Medication  
Collection and Distribution of Patient Diary 
6.2.9 
Visit 9 / Follow-Up Visit (28-35 days after study drug discontinuation) 
Assessments include: 
Safety Blood analysis 
Safety Urine analysis 
Visual Acuity (logMAR) 
Fundoscopic Exam (optional) 
Assessment of Adverse Events 
Concomitant Medication 
Collection of Patient Diary 
6.3 
Concomitant Medication / Treatment 
At each study visit, the investigator will review the patient diary and question the patient and/or 
the patient’s caregiver about any medication taken. All concomitant medications, including 
vitamins and supplements, will be recorded in the patient’s CRF with details of dose, route of 
administration, dates of administration and indication. 
The period for documentation of concomitant medication begins on the day of the Baseline Visit 
and ends on the day of the final study visit. Medication discontinued before the Baseline Visit 
should not be recorded in concomitant medication log in the CRF. Medication concomitant with 
an SAE reported after the final study visit should be listed on the SAE form. 
6.3.1 
Prohibited Concomitant Medication 
Intake of the following medication will lead to withdrawal from the study: 
 
any other investigational drug 
 
any other source of idebenone 
Any case of doubt should be discussed with the Sponsor's Medical Monitor and the outcome 
confirmed in writing. 
6.3.2 
Interaction with other medicinal products 
Idebenone is a weak inhibitor of CYP3A4 and therefore sensitive substrates with narrow 
therapeutic window such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, 
pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) 
should be administered with caution (please refer to the Idebenone Investigator’s Brochure with 
indication area: Neuro-Ophthalmology). 
 
6.4 
Study Completion 
A patient is considered to have completed the study if he/she has taken the study medication for 
24 months and attended Visit 8/Month 24. These results will be documented for each patient in 
the study. Completion or discontinuation of the study will be documented in the patient’s CRF.  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 31 of 50 
 
6.5 
Discontinuation / Withdrawal 
6.5.1 
Conditions for discontinuation/withdrawal 
Reasons that a patient may be withdrawn from the study include the following: 
 
adverse event(s) 
 
major protocol deviation/violation (e.g. Intake of any prohibited concomitant medication 
as listed in Section 6.3) 
 
inclusion criteria not met/exclusion criteria met 
 
genetic diagnosis reveals that a patient does not harbour a LHON-specific mtDNA mutation  
 
pregnancy 
 
lack of compliance with study medication 
 
patient withdrew consent 
 
lost to follow-up 
 
death 
 
other (reason to be documented) 
 
Each patient has the right to withdraw from the trial at any time for any reason without affecting 
the right to treatment by the investigator. The investigator also has the right to withdraw the 
patient if he/she judges it in the patient’s best medical interest. In either case, all attempts should 
be made to document the reason for withdrawal. Santhera Pharmaceuticals (Switzerland) Ltd 
reserves the right to request the withdrawal of a patient due to protocol deviation, administrative 
or other reasons. 
It is understood by all concerned that an excessive rate of withdrawals can render the study non 
interpretable, therefore every effort should be made to avoid unnecessary withdrawals. 
However, WHENEVER a patient is withdrawn from a trial, FOR WHATEVER REASON, a final 
study evaluation must be completed for that patient, including all Visit 9 evaluations if possible, 
and stating the reasons why the patient was withdrawn. All documentation concerning the patient 
must be as complete as possible. Withdrawals due to non-attendance must be followed-up by 
the investigator to obtain the reason for non-attendance. 
6.5.2 
Procedures for Handling Discontinued Patients 
Investigators should make every attempt to contact those patients who do not return for 
scheduled visits or follow-up.  
Whenever a patient is withdrawn from the study, all efforts should be made to complete and 
report the observations as thoroughly as possible. A final evaluation must be completed for that 
patient, including all Follow-up Visit evaluations (see Section 6.5.1) if possible, and documenting 
the reasons why the patient was withdrawn from the trial.  
Withdrawals due to intercurrent illnesses or AEs must be fully documented in the CRF with the 
addition of supplementary information if available and/or appropriate. Withdrawals due to non-
attendance must be followed-up by the investigator to obtain the reason for non-attendance. 
Information gathered should be described on the End of Study page of the CRF and on the 
appropriate forms (i.e., Adverse Events, Concomitant Medication). 
Withdrawn patients will not be replaced. 
6.6 
Treatment and Storage of Biological Samples 
6.6.1 
Safety Blood and Urine Samples 
Measurement tests for safety blood and urine analysis will be performed by the local laboratory 
according to their standard procedures. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 32 of 50 
 
7 
Efficacy Assessments 
7.1 
Visual acuity 
Visual acuity in both eyes will be assessed at every visit by a specialist in ophthalmology. 
Patients will be refracted to ensure that, at every study visit, optimum vision at 4 meters is 
achieved. When measuring acuity in the right eye the left eye is covered and the patient is asked 
to read down logMAR chart 1 slowly letter by letter. When a letter is read correctly the examiner 
indicates this on the score sheet (identical to the chart layout). Only one reading of a given letter 
is allowed. When the patient has difficulty, he or she is encouraged to guess. The distance to 
the chart is 4 meters. If, however, less than 20 letters are read correctly from the 4 meter rows, 
the patient’s distance to the chart will be reduced to 1 meter and the logMAR score is assessed 
at this distance in the same manner. Should the patient not be able to read any letters, the 
investigator will proceed to record whether VA is reduced to counting fingers (CF), hand motion 
(HM), light perception (LP), or no light perception. CF and HM are tested at a distance of about 
30 cm from the eye. The left eye will then be tested in the same way using chart 2. 
8 
Safety Evaluations 
8.1 
Adverse Events (AEs) 
The recording of AEs is an important aspect of study documentation. It is the responsibility of 
the Investigator to document all AEs according to the detailed guidelines set out below. 
The patient and/or his caregiver will be instructed to contact the Investigator immediately should 
the patient manifest any signs or symptoms perceived as serious during the period extending 
from the day of signature of the consent form up to and including the last visit. After this period 
of time, the Investigator should report to the sponsor only AEs that are serious and related to the 
study medication. 
8.1.1 
Definition of an Adverse Event 
An AE is defined as any untoward medical occurrence in a patient administered a medicinal 
product and which does not necessarily have a causal relationship with this treatment. This 
includes any noxious, pathological or unintended change in anatomical, physiological or 
metabolic functions as indicated by physical signs, symptoms and/or laboratory detected 
changes occurring in any phase of the study whether considered related to the study medication, 
or not.  
Exacerbation of pre-existing conditions or events, intercurrent illnesses, drug-drug or drug-food 
interactions, lack of efficacy, overdose, drug maladministration or accidental exposure, and 
dispensing errors should also be considered and reported as AEs (as SAE if they result in a 
Serious Adverse Event, see Section 8.2). Discrete episodes of chronic conditions occurring 
during the study period should be reported as AEs in order to assess changes in frequency or 
severity. 
Anticipated day-to-day fluctuations of pre-existing conditions that do not represent a clinically 
significant exacerbation need not be considered as AEs. Pre-existing conditions should be re-
assessed throughout the study and recorded as AE or SAE only if the frequency, severity, or 
character of the condition worsens. 
 
AEs should be documented in terms of diagnosis whenever possible; if a diagnosis is not yet 
available, signs and symptoms should be reported in the Adverse Event page of the CRF.  
 
AEs, regardless of seriousness, which occur prior to the day of signature of the consent form, 
will be documented in the Medical History form within the patient's CRF.  
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 33 of 50 
 
Hospitalization should not be considered as an AE (therefore also not an SAE) when it is due to: 
- 
Medical or surgical procedures planned before study entry; 
- 
Medical or surgical procedures for pre-existing medical conditions which did not increase 
in frequency, severity, or nature following initiation of the study; 
- 
Social or economic reasons. 
These cases must be recorded on the Hospitalization form of the CRF.  
8.1.2 
Adverse Events of Special Interest (AESI) 
The detection, monitoring and evaluation of potential risks of idebenone are addressed in the 
idebenone risk management plan. AESI correspond to the important potential risks which are 
identified in the safety specification and listed in the Risk Management Plan and in the 
corresponding interface between the European Risk Management Plan and EudraVigilance. 
Important potential risks are important risks for which there is some basis for suspicion of a 
causal association with the medicinal product of interest but where this association has not been 
confirmed and needs further confirmed or rejected as new data on come available. Currently, 
there are no important identified risks, i.e. important risk for which there is adequate evidence of 
an association with the medicinal product of interest, listed in the idebenone RMP. 
 
Therefore, particular attention should be paid to AESI that are described as follows as follows in 
this RMP and constitute important potential risks for idebenone: 
 
 
Abnormal liver function test (ALT, AST, total bilirubin, GGT) or hepatitis (liver disease) 
 
Blood count abnormalities (such as agranulocytosis, anaemia, leukocytopenia or 
thrombocytopenia) 
 
In order to be considered as AESI, the events should in first place qualify as AE according to 
the guidance presented in 8.1.1 above.  
Possible fluctuations of hepatic laboratory tests or blood count values which from medical 
history may be expected in the patient but which are not considered clinically relevant by the 
investigator should not be reported as AESI.  
For hepatic laboratory tests listed above any change below 1.5XULN usually are considered 
not to be clinically relevant, but this qualification as not clinically relevant should always remain 
a judgment by the investigator in the individual patient. 
For complete and accurate safety surveillance, the data collected on these pre-defined events 
will include as many details as possible to corroborate diagnosis.  
AESI should be reported using the designated section of the SAE report form and transmitted to 
UBC with 24 hours of learning of its occurrence, regardless severity and seriousness 
assessment. 
8.1.3 
Surveillance Period for Occurrence of Adverse Events 
All AEs occurring from the day of signature of the consent form to the date of last visit must be 
recorded on the Adverse Event page in the patient’s CRF, irrespective of severity or whether or 
not considered related to study medication. 
After this period of time, the investigator should report to the sponsor only AEs that are serious 
and related to the study medication (see Sections 8.2.2-8.2.4).  
8.1.4 
Recording Adverse Events 
The occurrence of AEs should be sought by non-directive questioning of the patient and/or his 
caregiver at each visit or phone call during the study. AEs also may be detected when they are 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 34 of 50 
 
volunteered by the patient during or between visits, or through physical examination, laboratory 
test, or other assessments. All AEs either observed by the Investigator or one of his clinical 
collaborators, or spontaneously reported by the patient or his caregiver will be evaluated by the 
Investigator.  
 
The nature of each event, date and time (where appropriate) of onset, severity, relationship to 
study medication and outcome should be established. Details of any symptomatic/corrective 
treatment should be recorded on the appropriate page of the CRF.  
 
All AEs should be treated appropriately. Treatment may include one or more of the following: no 
action taken (i.e. further observation only); study medication dosage adjusted or temporarily 
interrupted; study medication permanently discontinued due to this AE; drug therapy given; non-
drug therapy given. The action taken to treat the AE should be recorded on the Adverse Event 
page of the CRF. 
 
Once an AE is detected, it should be followed up until its resolution or until the last study visit. 
An assessment should be made at each visit (or more frequently, if necessary) of any changes 
in its severity, its suspected relationship to the study medication, the interventions required to 
treat it, and the outcome; this information should be recorded on the appropriate page of the 
CRF. If an AE changes significantly in severity during the study, a new record should be started 
(see also Section 8.1.7). 
8.1.5 
Assessment of Severity 
The severity of each AE should be assessed as described in the following table: 
Assessment 
Definition 
Mild: 
The AE causes discomfort but no disruption of normal daily 
activities, or results in clinically significant but mild abnormalities of 
laboratory and/or instrumental parameters. It is transient and 
recovers with or without treatment.  
Moderate: 
The AE causes significant discomfort, disrupts normal daily 
activities or results in clinically significant and marked abnormalities 
of laboratory and/or instrumental parameters. It requires treatment. 
Severe: 
The AE causes severe discomfort, prevents regular activities or 
results in clinically dangerous abnormalities of laboratory and/or 
instrumental parameters. It may be resistant to treatment or require 
discontinuation of the study medication. 
 
8.1.6 
Assessment of Causality 
Complete and accurate information is of critical importance to allow a meaningful causality 
assessment. Every effort should be made by the Investigator to explain each AE and assess its 
causal relationship if any, to study medication. Factors that should be evaluated include (but are 
not limited to): 
 Previous observations or reports of similar events during treatment with the study 
medication 
 Previous observations or reports of similar events during treatment with drugs of the same 
pharmacological class 
 Evidence of a plausible pharmacological mechanism 
 Causative or contributing role of the underlying disease 
 Evidence of similar or related conditions in the patient’s medical history 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 35 of 50 
 
 Causative or contributing role of concomitant medications (if administered) 
 Causative or contributing role of a protocol required procedure 
 
Investigators should refer to the Reference Safety Information section of the Investigator’s 
Brochure for a list of AEs that have been observed in clinical trials of idebenone and are thought 
to be associated its administration. 
On the basis of the available evidence, the Investigator should assess the causality of each AE 
by answering the following question: 
In your opinion, is there a reasonable possibility that the AE may have been caused by the study 
medication? 
 
No = Unrelated / Not-Suspected: the study medication is not suspected to reasonably 
possibly have contributed to the AE. The reported event can be explained by other 
and more likely aetiologies.  
 
Yes = Related / Suspected: the study medication is suspected to reasonably possibly have 
contributed to the AE. There is no evidence of plausible alternative aetiologies or 
they are considered to constitute insufficient or possibly non-exclusive causes for 
the reported event. 
8.1.7 
Follow-up of Adverse Events and Assessment of Outcome 
Investigators should follow-up AEs until resolution or until the last study visit, and an assessment 
should be made at each visit (or more frequently, if necessary) of any changes in its severity, its 
suspected relationship to the study medication, the interventions required to treat it, and the 
outcome; this information should be recorded in the CRF. 
If the severity of an AE changes significantly during the study period, a new record should be 
started indicating the change in severity. 
The outcome of each AE should be assessed as follows: 
 
Resolved 
 
Resolved with sequelae 
 
Ongoing at patient study conclusion 
 
Fatal 
 
Lost to follow up 
 
For follow-up of SAEs, see also Section 8.2.4. 
8.2 
Serious Adverse Events 
8.2.1 
Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence or effect at any dose, that: 
 
Results in death, 
 
Is life threatening*, 
 
Results in persistent or significant disability/incapacity†, 
 
Requires in-patient hospitalization‡ or prolongation of existing hospitalization, 
 
Is a congenital anomaly/birth defect in the offspring of a study patient, 
 
Is deemed, by the investigator, an important medical event that may jeopardise the 
patient or may require intervention to prevent one of the other outcomes listed above. 
Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization; or development of drug dependency or drug abuse. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 36 of 50 
 
* 
Life threatening - definition: An AE is life threatening if the patient was at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused death if it were more 
severe. 
† 
Disabling/incapacitating - definition: An AE is incapacitating or disabling if the event results in a 
substantial disruption of the patient's ability to carry out normal life functions. This definition is not 
intended to include experiences of relatively minor medical significance such as headache, nausea, 
vomiting, diarrhoea, influenza, or accidental trauma (e.g. sprained ankle). 
‡ 
Hospitalization - definition: In general, hospitalization signifies that the patient has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward for treatment that 
would not have been appropriate in the physician's office or out-patient setting. 
Hospitalization should not be considered as an AE (therefore also not an SAE)    when it is due to: 
- 
Medical or surgical procedures planned before study entry; 
- 
Medical or surgical procedures for pre-existing medical conditions which did not increase in 
frequency, severity, or nature following initiation of the study; 
- 
Social or economic reasons. 
These cases must be recorded on the Hospitalization form of the CRF. 
When in doubt as to whether an AE should be considered serious or not, the AE should be 
reported as SAE (= within 24 hours). 
8.2.2 
Reporting Serious Adverse Events and AESIs 
The investigator must report all SAEs/AESIs within 24 hours of becoming aware of the event, 
whether or not the SAE/AESI is considered to be related to the study medication.  
The appropriately completed SAE form (see Guidelines for Completing Serious Adverse Event 
(SAE) Forms) must be faxed or scanned and emailed to sponsor’s designee (see contact details 
below), who will acknowledge receipt within 1 working day. This initial notification should include 
minimal, but sufficient information to permit identification of the reporter, the patient, the suspect 
study medication, adverse event term, seriousness criteria and the investigator’s causality 
assessment. The investigator should not wait for additional information to fully document the 
event before sending the initial report.  
Each SAE/AESI should be followed-up in order to complete the collection of all missing 
information and address any relevant query requested by the sponsor. All newly available 
information collected on follow-up must be submitted to sponsor’s designee by faxing or emailing 
a duly filled-in SAE form within 24 hours from awareness (as for the initial report). The follow-up 
report should include information often not available at the time of the initial notification, e.g. 
medical history, concomitant medications, actions taken by the investigator and outcome of the 
event. Hospital discharge summaries and autopsy reports should be obtained where applicable. 
 
Contact for Safety 
reporting: 
United Biosource Corporation  
EU Safety Services 
Phone:  +41 22 596 44 44 
Fax:  
+41 22 596 44 46 
e-mail: EUSafety@ubc.com 
 
Investigators must report SAEs to the appropriate IRB/ethics committee if requested by the 
committee and/or according to local legal requirements. 
AEs which meet all of the following criteria: 
 
Serious 
 
Unexpected  
 
There is at least a reasonable possibility that there is a causal relationship between the 
event and the medicinal product 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 37 of 50 
 
The AEs meeting the above criteria will be classified as Suspected Unexpected Serious Adverse 
Reactions (SUSARs) and should be reported to the relevant IRB/Ethics Committee and to the 
relevant Health Authorities in accordance with applicable regulatory requirements for expedited 
reporting. It is the Sponsor’s responsibility to report SUSARs to central Ethics Committee/IRB 
and relevant Health Authorities, although this responsibility will be delegated to United Biosource 
Corporation (UBC). 
8.2.3 
Causality Assessment of Serious Adverse Events 
Every effort should be made by the investigator to explain each SAE and assess its causal 
relationship, if any, to study medication by answering the following question: 
In your opinion, is there a reasonable possibility that the SAE may have been caused by the 
study medication?  
No = Unrelated / Not-Suspected: the study medication is not suspected to reasonably 
possibly have contributed to the SAE. The reported event can be explained by other and 
more likely aetiologies (please specify which ones).  
Yes = Related / Suspected: the study medication is suspected to reasonably possibly 
have contributed to the SAE. There is no evidence of plausible alternative aetiologies or 
they are considered to constitute insufficient or possibly non-exclusive causes for the 
reported event. 
For further guidance on the assessment of causality, refer to Section 8.1.6. 
8.2.4 
Follow-up of Serious Adverse Events 
All SAEs reported from the date of signature of the consent form to the date of the last study visit 
must be documented in the SAE form and followed up until the event resolved, subsided, 
stabilized, disappeared or is otherwise explained or the study patient is lost to follow-up.  
Any SAEs experienced after this period should be reported to the sponsor if the investigator 
suspects a causal relationship to the study medication.  
All follow-up activities must be reported, if necessary on one or more consecutive SAE forms in 
a timely manner. All fields with additional or changed information must be completed and the 
form should be forwarded to sponsor’s designee within 24 hours from the receipt of new 
information.  
Recurrent episodes, complications, or progression of the initial SAE must be reported as follow-
up to the original episode, regardless of when the event occurs. This report must be submitted 
within 24 hours of the investigator receiving the follow-up information. An SAE that is considered 
completely unrelated to a previously reported one should be reported separately as a new event. 
8.3 
Treatment of Adverse Events 
Treatment of any AE is at the sole discretion of the investigator and according to current available 
best treatment. The applied measures should be recorded in the CRF of the patient. 
8.4 
Pregnancy 
Women participating in the study who become pregnant while taking study medication will be 
discontinued as per Section 6.5.1. 
Any pregnancy that occurs during the study, or before last study visit, must be recorded on a 
Clinical Trial Pregnancy form (see Guidelines for Completing Pregnancy Forms) and reported to 
the sponsor’s designee (see contact details above) within 24 hours of learning of its occurrence. 
The pregnancy should be followed up to determine its outcome (i.e. spontaneous or voluntary 
abortion, presence or absence of any birth defects, congenital abnormalities, or maternal and/or 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 38 of 50 
 
newborn complications) and it should include the investigator’s assessment of any possible 
relationship between the outcome and the exposure to the study medication.  
Women becoming pregnant while their partner is taking the study medication should be followed-
up in order to collect information about the outcome of their pregnancy. Consent to report 
information regarding these pregnancy outcomes should be obtained from the mother. 
Any SAE experienced during pregnancy (e.g. abortion, abnormal results from fetal examination) 
must be treated as an SAE and reported within 24 hours from awareness.  
8.5 
Anthropometric measurements 
8.5.1 
Weight and height (Visit 1 only) 
Weight will be recorded in kilogram (kg), to the nearest 100 grams, using always the same scale.  
Height is recorded in centimetres (cm) and measured in an upright position using a stadiometer. 
8.6 
Safety and Monitoring Measures  
8.6.1 
Physical Examination and Vital Signs 
Physical examination will include assessment of the skin, head, neck, ears, nose, throat, chest, 
lungs, heart, abdomen, lymph nodes, musculoskeletal system, vascular system, nervous system 
and any other physical conditions of note.  
Blood pressure will be measured in supine position. Supine blood pressure should be measured 
first after the patient has been lying down for 5 minutes.  
Blood pressures will be measured with a standardized mercury manometer; alternative validated 
methods of measurement may also be used. The point of disappearance of Korotkoff sounds 
(phase V) will be recorded as the diastolic blood pressure where a sphygmomanometer is used. 
Heart rate will be determined over 60 seconds in supine position following the recording of blood 
pressure.  
Respiratory rate will be determined over 60 seconds in supine position following the recording 
of blood pressure and heart rate. 
8.6.2 
Fundoscopic Exam 
A fundoscopic exam with pupil dilation will be performed at Visit 1/Baseline, Visit 6, and Visit 8 
in order to exclude any other underlying diseases that could be responsible for vision loss. An 
additional fundoscopic exam may be performed at Visit 9 (follow-up visit) if any abnormalities 
were observed at the previous Visit 8.  
8.6.3 
Safety Blood Sampling and Urine Analysis  
Measurement tests for safety blood and urine analysis will be performed at all visits. Blood 
samples for haematology, biochemistry and urine analysis will be analysed in local laboratories.  
10 ml of blood will be collected for safety haematology and biochemistry at each visit. Urine 
samples will also be collected at each visit.  
Haematology 
Safety haematological analysis will include: 
 
red blood cell count 
 
hemoglobin 
 
hematocrit 
 
red cell indices 
 
white blood cell count, including differential 
 
platelet count 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 39 of 50 
 
Biochemistry 
Safety biochemistry will include: 
 
sodium 
 
potassium 
 
chloride 
 
bicarbonate 
 
urea 
 
creatinine 
 
calcium 
 
inorganic phosphate 
 
glucose 
 
total bilirubin 
 
total protein 
 
albumin 
 
aspartate aminotransferase (AST) 
 
alanine aminotransferase (ALT) 
 
alkaline phosphatase 
 
gamma GT (GGT) 
 
creatine kinase (CK) 
 
cholesterol 
 
triglycerides 
 
uric acid 
Urine Analysis 
Safety urine analysis will include: 
 
pH 
 
protein 
 
glucose 
 
Pregnancy Test 
Pregnancy test can use:  
 
highly 
sensitive 
urine 
analysis  
or 
 
serum analysis 
 
ketones 
 
blood 
8.6.4 
Highly effective contraceptive measures  
Highly effective birth control methods (methods that can achieve a failure rate of less than 1% 
per year when used consistently and correctly) include: 
 
Combined (estrogen and progestogen containing) hormonal contraception (oral, 
intravaginal or transdermal) associated with inhibition of ovulation  
 
Progestogen-only hormonal contraception (oral, injectable or implantable) 
associated with inhibition of ovulation 
 
Intrauterine device (IUD) 
 
Intrauterine hormone-releasing system (IUS) 
 
Bilateral tubal occlusion 
 
Vasectomised partner1 
 
Sexual abstinence2 
 
1 Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual 
partner of the WCBP trial participant and that the vasectomised partner has received medical assessment 
of the surgical success. 
2 Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatments. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and 
the preferred and usual lifestyle of the subject. 
8.7 
Data Safety Monitoring Board (DSMB) 
The DSMB is an independent multidisciplinary group with expertise in the fields of clinical 
medicine relevant for the study indications, drug safety, and clinical trial statistics. The DSMB 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 40 of 50 
 
consists of a minimum of three members who have no role in the conduct of the trials, or any 
other conflict of interest. The DSMB assesses the safety of the interventions during the 
idebenone clinical development program, by reviewing interim and cumulative safety data. The 
DSMB provides recommendations about stopping or continuing the clinical development 
program, including any modifications which may be required to protect the safety of the subjects. 
The DSMB structure, responsibilities and procedures are described in details in a dedicated 
charter. 
9 
Data Evaluation and Statistics  
9.1 
General Considerations 
The present clinical investigation has the primary goal to determine whether administration of 
idebenone can maintain or improve vision in LHON patients. The investigation will be conducted 
as a prospective, multicenter, open-label trial. 
The following subsections summarize the statistical principles and procedures to be used in the 
analysis of this study. A more detailed description will be provided in a separate Statistical 
Analysis Plan (SAP) that will be finalized prior to database lock. The SAP will serve as a 
compliment to the protocol and supersedes it in case of differences. 
9.2 
Analysis Variables 
9.2.1 
Primary Endpoint 
 
Proportion of eyes with clinically relevant recovery of VA from Baseline or in which Baseline 
VA better than 1.0 logMAR was maintained at Month 12, compared to matching external 
natural history control group  
CRR of VA is defined below and illustrated in Figure 1:  
 
For any “off-chart” VA category (CF, HM, LP or NLP), CRR in VA is defined as the ability to 
read at least 5 letters “on-chart” (the equivalent of one full chart line) at the last available 
assessment  
 
For “on-chart” VA, CRR in VA is defined as the ability to read at least 10 additional letters 
(equivalent to two chart lines) at the last available assessment  


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 41 of 50 
 
Figure 1: VA categories 
 
 
CRR from Baseline for eyes (treated independently) and for patients (with at least one eye with 
CRR) will be determined. 
Proportion of eyes with CRR of VA from Baseline or in which Baseline VA better than 1.0 logMAR 
was maintained at Month 12, will be compared to a matching external natural history control 
group which is generated as defined below. 
Data from the previously conducted Case Record Survey (CRS; SNT-IR-006) and from the newly 
ongoing CRS (SNT-CRS-002) will be used to generate a combined CRS control dataset which 
will be applied as an external natural history control group for comparison against patients 
treated with idebenone in this open label study. All patient VA data in the combined CRS control 
dataset will have VA values observed at a known time since the onset of symptoms and all VA 
data subsequently captured, regardless of the assessment time, will be included in the combined 
CRS database. This approach will be used to compare data collected in this open label study to 
the combined CRS idebenone naïve patients control dataset for the primary endpoint. 
In order to optimize the comparability of patient data in the combined CRS control dataset to this 
open label study for the primary endpoint, a subgroup of patient VA data points from the CRS 
control dataset will be prospectively defined as follows: 
1. 
Since there is no treatment to be considered in the combined CRS, in principle any VA 
observation at any time point after the onset of symptoms in any eye can be used as a 
Baseline for that eye. The primary outcome measure in the open label study is the VA at 
12 months after Baseline. Therefore, using a “window” of ±3 months, any eye with a VA 
observation at any time point in the combined CRS control dataset which has a follow-up 
VA assessment within 12±3 months will be retained for use as a possible Baseline 
observation. All such possible Baseline observations and subsequent VA assessments will 
form the CRS control dataset subgroup to be compared to the Baseline of the open label 
study. 
2. 
In the open label study, the average time from the onset of symptoms to the start of 
idebenone treatment will be calculated once all data is available. The start of the 
idebenone treatment will be used as the Baseline in the statistical analyses.   
3. 
For each VA observation retained in the CRS control dataset subgroup, for each eye the 
time from the onset of symptoms at each possible Baseline time point will be calculated. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 42 of 50 
 
4. 
For each eye in the CRS control dataset subgroup, the VA observation which is closest in 
time since the onset of symptoms to the average time since onset of symptoms at Baseline 
calculated for the open label study (see 2) will be selected as the Baseline VA observation 
for that eye. Any eye in the CRS control dataset subgroup with a time since onset >6 
months after the average time since onset at Baseline in the open label study will be 
discarded. The resulting data set will from the “final CRS control dataset”. In this way, 
Baseline observations in the final CRS control dataset will be closely matched to the 
Baseline in the open label study. 
5. 
The change from Baseline in VA at 12±3 months for each eye in the final CRS control 
dataset selected as described for the primary endpoint will be compared to the change 
from the Baseline visit to the visit scheduled at Month 12 in the open label study.  
This algorithm will guarantee that the time from the onset of symptoms to the Baseline 
assessment is comparable between the final CRS control dataset and the open label study. 
9.2.2 
Secondary Endpoints 
 
Components of the primary endpoint: 
- 
Proportion of eyes with CRR of VA from Baseline at Month 12 compared to matching 
external natural history control group 
- 
Proportion of eyes in which Baseline VA better than 1.0 logMAR was maintained at 
Month 12 compared to matching external natural history control group 
 
Proportion of eyes in patients treated with idebenone >1 year after the onset of symptoms 
with CRR of VA from Baseline or in which Baseline VA better than 1.0 logMAR was 
maintained at Month 12 compared to external natural history control group, in all patients 
and classified by mutation 
 
Proportion of eyes and patients treated with idebenone ≤1 year after the onset of symptoms 
with CRR of VA from Baseline or in which Baseline visual acuity better than 1.0 logMAR was 
maintained following 6, 18 and 24 months of treatment with idebenone compared to matching 
external natural history control group, in all patients and classified by mutation 
 
Proportion of eyes/patients treated with idebenone ≤1 year or >1 year after the onset of 
symptoms with “Off-chart” VA at Baseline in whom VA improves to better than 1.60 logMAR 
by Month 6, 12, 18 and 24  
 
Proportion of eyes/patients treated with idebenone ≤1 year or >1 year after the onset of 
symptoms with VA in the categories of better than 1.0 logMAR, 1.0 to 1.68 logMAR and 
above 1.68 logMAR at each assessment time point up to Month 24 
 
Safety as assessed by AE count and laboratory analyses during the study 
The external natural history control group for the eyes with Baseline >1 year after the onset of 
symptoms in the OLS will be generated as follows: 
 
All available eyes in the external natural history dataset will be considered, regardless of 
whether the eye in question was used in the control group for the primary objective or not 
 
All VA assessments data collected >1 year after the onset of symptoms are considered as 
potential baseline values 
 
If a potential baseline value does not have a follow-up VA assessment within 12±3 months, 
it will be excluded 
 
The remaining potential baseline values will be categorized in the following time since onset 
bins: between >1-2 years, >2-3 years, >3-4 years or >4-5 years 
 
If there are several potential baseline values for the same eye in the same bin, the eye with 
the baseline value closest to the midpoint of the bin will be selected 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 43 of 50 
 
 
The selected baseline value and the follow-up VA assessment within12±3 months in the 
same eye will be included in the external natural history control group for the eyes in the OLS 
with baseline >1 year after the onset of symptoms 
 
It should be noted that different cuts (various baseline with corresponding follow-up VA 
values) from the same eye can be used multiple times, both for the analysis of the primary 
endpoint (only once) and for the analysis of eyes with baseline >1 year after the onset of 
symptoms (not more than once within each of the four bins defined above) 
9.2.3 
Safety Variables 
Safety will be assessed based on a series of parameters, including: 
 
Adverse events/AESIs 
 
Physical examinations 
 
Vital signs 
 
Clinical laboratory values (haematology, biochemistry and urine analysis) 
9.3 
Analysis Populations 
9.3.1 
Intent-To-Treat Population 
The Intent-To-Treat (ITT) population will include all enrolled patients who received at least one 
dose of the study medication and provide at least one post-baseline VA assessment and are 
confirmed carriers of only one of the three major LHON mtDNA: G11778A, G3460A or T14484C. 
9.3.2 
Safety Population 
The Safety Population will include all enrolled patients who received at least one dose of study 
medication. 
9.4 
Analysis Methods 
9.4.1 
Analysis of Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized with descriptive statistics. 
Demographic and Baseline analysis will be performed on the Intention-To-Treat population. 
9.4.2 
Efficacy Evaluation 
The primary analysis will be based on Intention-To-Treat principle as change from Baseline. 
The primary endpoint will be analysed using a logistic regression model. The binary response 
will be used as the dependent variable. The independent variables include the treatment group 
(idebenone treated patients versus untreated control group) and mutation group (G11778A, 
G3460A, T14484C). The difference between the idebenone treated patients versus untreated 
control group will be estimated with odds ratio estimates, 95% confidence intervals and two-
sided p-values. 
All patients who have at least one post-baseline assessment at 12±3 months after Baseline will 
be included in the primary analysis. This approach is chosen due to the lack of pre-defined visit 
structure in the control dataset. As a sensitivity analysis, the impact of incomplete data will be 
assessed by analysing the primary endpoint with a generalized linear mixed model. For this 
purpose, the SAS GLIMMIX procedure for binomial data with logic link will be used to estimate 
the treatment differences. Factors similar to the ones used for the primary endpoint will be 
included in the model. The data from the control dataset will be classified as visits by selecting 
the assessment which is closest to 6, 12, 18 and 24 months from all assessments conducted 
within a window of ±3 months. The treatment difference at Month 12 will be estimated using 
contrasts. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 44 of 50 
 
The secondary endpoints based on counts of eyes/patients will be analysed with methods similar 
to the primary endpoint. 
The baseline VA will be used as a covariate and treatment group and mutation as fixed factors. 
A mixed model for repeated measures (MMRM) will be used to assess the impact of incomplete 
data. The responder status (CRR or no CRR) will be used as independent variable instead of 
the treatment group, as this data are not available in the control dataset. 
At least the following subgroups will be analysed: 
 
Each primary LHON mtDNA mutation separately (G11778A, G3460A, T14484C)  
9.4.3 
Safety Evaluation 
The disposition of the patients will be summarized by tabulating the number of enrolled, 
completed and discontinued patients. The reasons for premature discontinuations will be 
tabulated. The extent of exposure will be summarized by tabulating the duration of the study 
treatment.  
All adverse events (AEs) will be coded using the MedDRA dictionary. The treatment-emergent 
AEs (i.e., events which start or worsen during the study treatment) will be tabulated by system 
organ class and preferred term. Both subject and event counts will be calculated. In addition, the 
treatment-emergent AEs will be evaluated by severity and by relationship to the study treatment. 
The serious AEs and AEs leading to a premature discontinuation will also be summarized. 
The clinical laboratory variables and vital signs will be summarized descriptively, including a 
tabulation of normal and abnormal values. 
9.5 
Analyses 
The final analysis for the primary endpoint will be conducted at the time when all subjects 
enrolled in this open label intervention study have completed Visit 6/Month 12. The following 
efficacy and safety parameters will be reported: 
Efficacy (primary endpoint): 
Proportion of eyes in patients treated with idebenone ≤1 year after the onset of symptoms with 
CRR of VA from Baseline or in which Baseline VA better than 1.0 logMAR was maintained at 
Month 12, compared to matching external natural history control group  
Safety (secondary endpoint): 
The count of patients who experienced abnormal biochemistry, haematology and/or urine test 
results will be reported, compared to the Baseline assessments. 
A detailed analysis plan will be prepared as part of the SAP prior to database lock. 
Final analyses will be conducted and a Clinical Study Report prepared when the last patient has 
left the study. 
9.6 
Sample Size and Power Considerations 
The present study is designed to provide sufficient statistical power for a pre-planned indirect 
comparison of the primary endpoint against an external natural history control group.  
As defined in the original LEROS study protocol (Version1.0, 29 January 2016, Section 9.6), the 
sample size calculation for LEROS assumed an expected 24% responder rate in the external 
natural history control group (combined data from SNT-IR-006 and SNT-CRS-002). The protocol 
defines a pre-planned check of the estimate of responder rate in the control group, once the 
enrolment of the new natural history study (SNT-CRS-002) has been completed. In case the 
responder rate in the control group is different from 24%, a sample size re-calculation using the 
updated control group estimate can be considered. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 45 of 50 
 
As SNT-CRS-002 study was completed, the data collected in the natural history studies has now 
been checked for the estimate of the responder rate. Based on the combined data from 175 
eyes in the two natural history studies (SNT-IR-006 and SNT-CRS-002), the estimated 
responder rate is below 22%, i.e. lower than the initially expected rate of 24%. Although the 
determination of the exact responder rate for the natural history studies requires final data from 
the LEROS study for matching purposes, it is reasonable to assume that the responder rate of 
the natural history studies is not higher than 22%. The sample size for LEROS study is therefore 
re-calculated using the same methods as in the original protocol (Version1.0, 29 January 2016). 
In order to reach a power of 90% for the comparison of the responder rates between the natural 
history studies (assumed to be 22% instead of 24%) and the LEROS study (assumed to be 40%, 
as defined in the protocol), evaluable data from altogether 110 eyes from the LEROS study is 
required. In order to account for a drop-out rate of 30% (as defined in the protocol), at least 80 
patients (equal to 160 eyes) will be enrolled to the LEROS study. 
The sample size calculation was done with nQuery Advisor version 8.3. 
For the sample size for the eye treated >1 year after the onset of symptoms and the 
corresponding external natural history control group, the aim is to collect VA data from same 
number of eyes as for the primary objective in order to compare the patients treated ≤1 and >1 
year since the onset of symptoms and to compare patients treated with Raxone >1 year since 
the onset of symptoms with the corresponding natural history control group, assuming sufficient 
natural history control data can be collected to generate the natural history control group as 
described in 9.2.2. 
9.7 
Quality Assurance of Data 
All data collected will be entered into a validated computerised clinical data management system.  
Analysis of the data will only be performed after all queries have been resolved using appropriate 
software for analysis. 
Data management and data analysis will be performed according to a prospectively prepared 
plan and in compliance with the QA system of the data management and data analysis provider. 
10 
Ethics, Regulatory and Administrative Considerations 
The study will be conducted according to the Declaration of Helsinki, Directive 2001/20/EC, 
Guideline for Good Clinical Practice (GCP) CPMP/ICH/135/95, the US  Code of Federal 
Regulations governing Protection of Human Subjects (21 CFR 50), Financial Disclosure by 
Clinical investigators (21 CFR 54), Institutional Review Boards (21 CFR 56), Investigational New 
Drug Application (21 CFR 312), and Applications for FDA Approval to Market a New Drug (21 
CFR 314),and applicable local regulatory requirements and laws.  
10.1 Institutional Review Board (IRB) / Independent Ethics Committee (IEC) 
The IRB/IEC must be constituted according to the local laws/customs of each participating 
country. It is recommended that it should include:  
(a) At least 5 members 
(b) At least one member whose primary area of interest is in a non-scientific area 
(c) At least one member who is independent of the institution/ study site. 
Only those IRB/IEC members who are independent of the investigator and the sponsor of the 
study should vote/ provide opinion on study-related matters. 
This protocol and any other documents that the IRB/IEC may need to fulfil its responsibilities, 
including the Patient Information and Informed Consent Form, patient recruitment procedures, 
and information about payments and compensation available to patients, will be provided by the 
Study Sponsor to the Principal Investigator, and will be submitted to the appropriate Committee 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 46 of 50 
 
or Board by the Principal Investigator, and their written unconditional approval should be in the 
possession of the investigator and the sponsor before commencement of the study. Relevant 
Santhera Pharmaceuticals (Switzerland) Ltd. data will be supplied by the Sponsor to the 
hospital/university/independent IRB/IEC for the protocol's review and approval. The IRB/IEC’s 
unconditional approval of the protocol and the written informed consent statement will be 
transmitted by the Sponsor. This approval must refer to the study by exact protocol title and 
number, and should identify the documents reviewed and state the date of review. 
No deviations from, or changes to, the protocol should be initiated without prior written IRB/IEC 
approval/favorable opinion of an appropriate amendment, except when necessary to eliminate 
immediate hazards to the patients (Urgent Safety Measure USM) or when the change(s) involves 
only logistical or administrative aspects of the study (e.g., change of monitor(s), telephone 
number(s)). In case the investigator takes an Urgent Safety Measure, the investigator shall 
inform Santhera representatives as soon as possible but at least within 24 hours and ensure 
that IRB/IEC is informed. Such modifications will be submitted to the IRB/IEC for information 
only. However, written verification that the modification was submitted should be obtained. The 
investigator will transmit approvals/verifications to the Sponsor, in writing. 
The investigator must inform the IRB/IEC of: 
 
all subsequent protocol amendments, informed consent changes or revisions of other 
documents originally submitted for review 
 
serious and/or unexpected AEs occurring during the study, where required 
 
all subsequent protocol modifications (for information) 
 
new information that may affect adversely the safety of the patients or the conduct of the 
study 
 
an annual update and/or request for re-approval, where required 
 
study completion, where required. 
10.2 Authorities 
The procedures laid out in 21 CFR 50, 54, 56, 312, 314 and/or local laws must be followed and 
all documents must be submitted to all concerned authorities before the clinical study may 
commence.  
10.3 Patient Information and Informed Consent 
The principles of informed consent in the Declaration of Helsinki must be implemented in the 
clinical study before any protocol-specified procedures or interventions are carried out. 
Information should be given in both oral and written form whenever possible and deemed 
appropriate by the IRB/IEC. 
10.4 Monitoring 
This trial will be managed and monitored in accordance with the ICH Guideline for Good Clinical 
Practice (ICH Topic E6, Integrated Addendum E6 (R2), 2016). The Quality Risk Assessment of 
the study is performed according to Santhera SOP050. A Clinical Trial  Risk Assessment and 
Management Plan for this study will be developed and maintained during the study, and will 
define and document tasks and scope of centralized, on-site monitoring, as well as QA activities 
such as systems’ and site audits. 
It is understood that Santhera Pharmaceuticals (Switzerland) Ltd. or their representative will 
contact and visit the investigators regularly for monitoring purposes. The monitor will be allowed, 
on request, to inspect the various records of the trial (CRFs and other pertinent data, provided 
that patient confidentiality is maintained in accordance with local requirements). It will be the 
monitor's responsibility to inspect the CRFs at regular intervals throughout the study, to verify 
the adherence to the protocol and the completeness, consistency and accuracy of the data being 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 47 of 50 
 
entered. The monitor should have access to laboratory test reports and other patient records 
needed to verify the entries on the CRF. The investigator (or her/his deputy) agrees to cooperate 
with the monitor to ensure that any problems detected in the course of these monitoring visits 
are resolved. 
Before any patients can be enrolled an Initiation Visit will be conducted. The investigator and the 
full study site staff must be available at this visit. All staff must have an Initiation Visit before they 
conduct any study specific procedures. 
10.5 Audit and Inspection 
Investigator sites, the study database and study documentation may be subject to quality 
assurance audits during the course of the study either by Santhera Pharmaceuticals 
(Switzerland) Ltd., or their appointed representatives. In addition, regulatory bodies at their 
discretion may conduct inspections. 
10.6 Source Documents 
The investigator(s)/institutions(s) will permit study-related monitoring, audits, IRB/IEC review, 
and regulatory inspection(s) providing direct access to source data/documents. 
The investigator shall permit the authorized sponsor, agents of the sponsor, and regulatory 
agency employees to enter and inspect any site where the drug or records pertaining to the drug 
are held, and to inspect and copy all records relating to an investigation, including subject 
records. Completed CRFs must be made available for review by the sponsor, agents of the 
sponsor, the clinical monitor and the regulatory agencies. To ensure the accuracy of data 
submitted, it is mandatory that representatives of the sponsor and of the regulatory agencies 
have direct access to source documents (i.e., subject medical records, charts, laboratory reports, 
etc.). Subject confidentiality will be protected at all times. 
10.7 Data Protection 
Personal and sensitive personal data will be treated as confidential. The results of the study will 
be made available for review by authorized representatives of Santhera Pharmaceuticals 
(Switzerland) Ltd. and/or submitted to one or more sponsor offices worldwide, the ethics 
committee and regulatory authorities. 
For this purpose the data may be transferred to other countries. The data collected from this 
study are considered as personal/sensitive data. 
Prior to the subject’s enrolment in the study, the subject’s consent is required for the data to be 
used for these purposes and to gain direct access to their medical records for data verification 
purposes. 
The subject’s must be assured that their identity will be protected. To facilitate this, a unique 
identification code will be assigned by the investigator to each study subject. This will be used 
instead of the subject’s name and cross referenced with the subject’s date of birth (according to 
country regulations, at the minimum the year and at the maximum the year and month will be 
collected) when reporting AEs and /or other study related data. 
10.8 Case Report Forms 
The Case Report Form (CRF) and the protocol are both confidential. The CRF will remain the 
property of Santhera Pharmaceuticals (Switzerland) Ltd. at all times. Conventional NCR paper 
CRFs or Electronic Data Capture (EDC) will be used for this study. Appropriate information will 
be supplied to the centres in the CRF Completion Guidelines. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 48 of 50 
 
The CRFs will be supplied by Santhera Pharmaceuticals (Switzerland) Ltd. All CRFs are to be 
completed by the examining personnel and reviewed and signed by the investigator(s). CRFs 
must accurately reflect data contained in subjects’ records (i.e. source documents). 
10.9 Investigator Site File 
At the beginning of the study, an investigator’s study file will be established at the study centre. 
The investigator/institution is responsible for maintaining the study documents as specified in 
the guideline for ICH-GCP (CPMP/ICH/135/95) and as required by the applicable regulatory 
requirement(s). The investigator/institution must take measures to prevent accidental or 
premature destruction of these documents. 
The following guidelines, instructions and certifications are regarded as relevant supplements 
and will be provided for the investigator's study file at each centre: 
 
IB 
 
The approval of the relevant ethics committees 
 
List of participating centres 
 
Instructions for completion of the CRF 
10.10  Premature Termination of the Study 
If the study is prematurely terminated or suspended, Santhera Pharmaceuticals (Switzerland) 
Ltd. will inform promptly the investigators/institutions, and the regulatory authority(ies) of the 
termination or suspension and the reason(s) for the termination or suspension. The IRB/ethics 
committee will also be informed promptly and provided with the reason(s) for the termination or 
suspension by Santhera Pharmaceuticals (Switzerland) Ltd. or by the investigator/institution, as 
specified by the applicable regulatory requirement(s). 
Potential reasons for premature termination of the study include: 
 
Unacceptable safety concerns of the study drug being studied and the safety of 
participants is no longer assured. 
 
The study objectives can be answered distinctly after an intermediate analysis. 
The recruitment of trial participants is insufficient and the successful termination of the clinical 
trial does not seem to be possible. 
10.11  Clinical Study Report 
Santhera Pharmaceuticals (Switzerland) Ltd. or its representative will prepare a final integrated 
clinical/statistical report which is compliant with the ICH Harmonised Tripartite Guideline: 
Structure and content of clinical study reports (ICH E3). 
10.12  Patient Insurance and Indemnity 
Santhera Pharmaceuticals (Switzerland) Ltd. will provide the insurance in accordance with local 
guidelines and requirements as a minimum for the subjects participating in this study. The terms 
of insurance will be kept in the study files. 
10.13  Amendments to the Protocol 
Modifications of the signed protocol, where substantial, are only possible by approved protocol 
amendments and with the agreement of all responsible persons. The procedure for approval of 
a protocol amendment is identical to that for approval of the protocol. The IRB/IEC must be 
informed of all substantial amendments and should be asked for its opinion as to whether a full 
re-evaluation of the ethical aspects of the study is necessary by the committee. This should be 
fully documented. 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 49 of 50 
 
The investigator must not implement any deviation from, or change to the protocol, without 
discussion with, and agreement by Santhera Pharmaceuticals (Switzerland) Ltd. and prior 
review and documented approval/favourable opinion of the amendment from the relevant 
IRB/ethics committee, except where it is necessary to eliminate an immediate hazard to study 
subjects, or where the change(s) involves only logistical or administrative aspects of the study, 
i.e. non-substantial (e.g. change in monitor(s), change of telephone number(s)). 
Protocol amendments will be submitted to the appropriate authority(ies) as required by the 
applicable regulatory requirement(s). 
10.14  Disclosure of Information 
In signing the final protocol, every participating investigator agrees to keep all information 
concerning the study and the investigational product confidential. The confidentiality obligation 
applies to all personnel involved at the investigational site. 
10.15  Definition of End of Study  
The end of the trial is defined as the Last Patient Last Visit date. Last Patient Last Visit is either 
the date of the last patient visit or the last patient to complete the study, or the date at which the 
last data point from the last patient, which was required for statistical analysis (i.e. key safety 
and efficacy results for decision making) was received, whichever occurs later. 
At the end of the study, in countries where the drug, is not commercially available, every effort 
will be made to assure continued access to idebenone to the patients who the investigator 
believes derived and are still deriving a benefit from treatment administration and a continuous 
use is clinically indicated, according to the local specific regulation. 
10.16  Publication and Presentation Policy 
The results of this study will be published and/or presented at scientific meetings in a timely 
manner. Any formal publication of study results will be a collaborative effort between Santhera 
Pharmaceuticals (Switzerland) Ltd. and the investigator(s). All manuscripts or abstracts will be 
reviewed and approved in writing by Santhera Pharmaceuticals (Switzerland) Ltd. prior to 
submission. 
10.17  Archiving and Data Retention 
Copies of all study documents must be retained by the sponsor and investigator for a minimum 
of 2 years after the last marketing application has been approved or the drug is withdrawn. The 
sponsor will notify the investigator when documents can be destroyed. The final database will 
be archived by Santhera Pharmaceuticals (Switzerland) Ltd. according to regulatory 
requirements. 
10.18  Registration of the Clinical Trial in a Publicly Accessible Database  
The Sponsor has registered this clinical trial in a publicly accessible database (such as EudraCT 
or clinicaltrials.gov) before recruitment of the first subject, in compliance with the Declaration of 
Helsinki. 
ClinicalTrials.gov Identifier: NCT02774005. 
 
 


 
SNT-IV-005_v2.1_US_6Mar2019 
Confidential 
 
Page 50 of 50 
 
11 
References 
Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, Sadun F, Carta A, 
Guerriero S, Simonelli F, Sadun AA, Aggarwal D, Liguori R, Avoni P, Baruzzi A, Zeviani M, 
Montagna P, Barboni P. Idebenone treatment in Leber's hereditary optic neuropathy. Brain. 2011 
Sep;134(Pt 9):e188. Epub 2011 Aug 2. 
Gueven N, Faldu. Idebenone treatment in Leber’s hereditary optic neuropathy: rationale and 
efficacy. Expert Opinion on Orphan Drugs. 2013, (2013) 1(4): 331-339. 
Gueven N. Optic Neurodegeneration: Time to Act. Biology and Medicine, 2014. (epub ahead of 
print). 
Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-Dependent 
Redox Cycling of idebenone: Effects on Cellular Redox Potential and Energy Levels. PLoS One, 
2011;6(3):e17963. 
Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Griffiths PG, 
Hudson G, Chinnery PF, Yu-Wai-Man P. 2009. Quality of Life in Patients with Leber Hereditary 
Optic Neuropathy. Investigative Ophthalmology & Visual Science 2009, 50: 3112-3115. 
Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. A randomized 
placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011; 134: 
2677-2686. 
Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding 
AE, Govan G, Bolhuis PA, Norby S. Primary pathogenic mtDNA mutations in multigeneration 
pedigrees with Leber hereditary optic neuropathy. Am J Hum Genet, 1996; 66: 332-335. 
Mascialino B, Leinonen M, Meier T. Meta-analysis of the prevalence of Leber hereditary optic 
neuropathy mtDNA mutations in Europe. Eur J Ophthalmol. 2012; 22(3): 461-465.  
Newman N, Biousse V. Hereditary optic neuropathies. Pediatric Ophtalmology and Strabismus 
2013. 561-570. 
Sadun AA, Morgia CL, Carelli V. Leber’s hereditary optic neuropathy. Curr Treat Options Neurol. 
2011; 13(1), 109-117. 
Clinical Trial Facilitation Group Guidance on contraception 2014, last checked on 11 Sep 2018, 
available 
at: 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf 
 

SAP_001.pdf: